[ { "date": "2026-04-27", "title": "Ibogaine cardiac safety concerns will materially slow or condition U.S. regulatory pathways, requiring mandatory cardiac monitoring protocols that will significantly increase deployment costs and complexity", "confidence": 76, "category": "regulation", "geography": "USA", "resolve_date": "2026-07-26", "tags": [ "ibogaine", "FDA", "REMS", "cardiac" ], "status": "pending", "priority": "high", "plain_title": "", "plain_what": "" }, { "date": "2026-04-27", "title": "Ibogaine will become the central contested exhibit in the 2026-2027 psychedelic safety culture war, simultaneously weaponized by pro-regulation and anti-prohibition advocates", "confidence": 78, "category": "culture", "geography": "Global", "resolve_date": "2027-06-30", "tags": [ "ibogaine", "media", "policy", "culture-war" ], "status": "pending", "priority": "high", "plain_title": "", "plain_what": "" }, { "date": "2026-04-27", "title": "Psilocybin will be the first classic psychedelic to receive FDA NDA acceptance for review for treatment-resistant MDD, with acceptance by Q2 2028", "confidence": 74, "category": "regulation", "geography": "USA", "resolve_date": "2028-06-30", "tags": [ "psilocybin", "FDA", "MDD", "EPISODE" ], "status": "pending", "priority": "high", "plain_title": "", "plain_what": "" }, { "date": "2026-04-27", "title": "Fluoxetine-psychedelic interaction data will be incorporated into FDA guidance requiring standardized SSRI washout criteria for psychedelic NDA submissions within 24 months", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2028-04-30", "tags": [ "FDA", "SSRI", "fluoxetine", "drug-interaction", "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "", "plain_what": "" }, { "date": "2026-04-28", "title": "No psychedelic substance is rescheduled from Schedule I to Schedule II or III in the United States before January 1, 2029", "confidence": 77, "category": "regulation", "geography": "USA", "resolve_date": "2029-01-01", "tags": [ "Schedule I", "rescheduling", "DEA", "psychedelics" ], "status": "pending", "priority": "high", "plain_title": "", "plain_what": "" }, { "date": "2026-04-28", "title": "Oxa-noribogaine enters a human Phase 1 clinical trial before October 31, 2027", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2027-10-31", "tags": [ "ibogaine", "oxa-noribogaine", "Phase 1", "cardiac safety" ], "status": "pending", "priority": "high", "plain_title": "", "plain_what": "" }, { "date": "2026-04-28", "title": "Ibogaine's cardiac safety profile causes at least one major clinical trial sponsor to publicly pause or redesign an ibogaine IND before December 31, 2027", "confidence": 70, "category": "regulation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "ibogaine", "cardiac safety", "IND", "clinical hold" ], "status": "pending", "priority": "high", "plain_title": "", "plain_what": "" }, { "date": "2026-04-28", "title": "FDA issues a formal guidance document specifically addressing psychedelic-SSRI pharmacodynamic interactions and washout requirements for psychedelic clinical trials before December 31, 2027", "confidence": 38, "category": "regulation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "FDA", "SSRI", "washout", "psychedelics", "guidance" ], "status": "pending", "priority": "medium", "plain_title": "", "plain_what": "" }, { "date": "2026-04-28", "title": "CMPS (Compass Pathways) closes below $7.00 on at least one trading day before June 30, 2026", "confidence": 45, "category": "markets", "geography": "USA", "resolve_date": "2026-06-30", "tags": [ "CMPS", "Compass Pathways", "stock price", "psychedelic biotech" ], "status": "pending", "priority": "medium", "plain_title": "", "plain_what": "" }, { "date": "2026-04-29", "title": "No ibogaine product achieves FDA approval before 2030", "confidence": 84, "category": "regulation", "geography": "USA", "resolve_date": "2030-01-01", "tags": [ "ibogaine", "FDA" ], "status": "pending", "priority": "high", "plain_title": "No ibogaine product gets FDA approval before 2030", "plain_what": "Ibogaine is a plant compound that some people use to treat addiction, but it can damage your heart in serious ways \u2014 causing dangerous irregular heartbeats. The FDA (the US drug regulator) won't approve it as medicine until someone runs long, careful studies proving it's safe for the heart. Those studies don't exist yet and probably won't be done by 2030." }, { "date": "2026-04-29", "title": "No federal ibogaine approval pathway is established before 2029", "confidence": 76, "category": "regulation", "geography": "USA", "resolve_date": "2029-01-01", "tags": [ "ibogaine", "FDA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "No federal ibogaine approval pathway established by 2029", "plain_what": "An approval pathway means the government has a clear set of rules and steps for how ibogaine could become legal medicine. Right now it doesn't. The FDA needs cardiac safety data, the DEA (which controls what drugs are illegal) won't change ibogaine's legal status without the FDA moving first, and Congress hasn't written any special laws to speed this up. None of those things will happen by 2029." }, { "date": "2026-04-29", "title": "Fluoxetine-psychedelic drug-drug interaction research generates at least five independent replication studies published in peer-reviewed journals by 2028-04-29", "confidence": 58, "category": "research", "geography": "USA", "resolve_date": "2028-04-29", "tags": [ "SSRI", "drug-drug interaction", "psychedelics", "clinical trials" ], "status": "pending", "priority": "medium", "plain_title": "Five independent studies replicate fluoxetine-psychedelic interaction by April 2028", "plain_what": "Fluoxetine is Prozac, one of the most common antidepressants. Early research suggests it might interact badly with psychedelics, making them less effective or more dangerous. Scientists want to confirm this is real, but they need five separate research teams to run the same experiment and get the same results. That's hard to do in two years \u2014 it takes time to recruit people, run the study, and publish the results." }, { "date": "2026-04-29", "title": "Fluoxetine-psychedelic drug-drug interaction becomes a required screening criterion in federally funded psychedelic trials by 2028-04-29", "confidence": 52, "category": "research", "geography": "USA", "resolve_date": "2028-04-29", "tags": [ "SSRI", "drug-drug interaction", "psychedelics", "FDA", "clinical trials" ], "status": "pending", "priority": "medium", "plain_title": "Fluoxetine-psychedelic screening becomes required in federal psychedelic trials by April 2028", "plain_what": "This means the FDA (the US drug regulator) would make it official rule: if you're running a federally funded psychedelic study, you must screen people to see if they take fluoxetine. If that interaction is real and dangerous, the FDA will probably make this a rule \u2014 but that takes time, and it won't happen until the evidence is really solid." }, { "date": "2026-04-29", "title": "DEA completes its Schedule I review process for psychedelics without rescheduling any substance to Schedule II or III before 2028-01-01", "confidence": 77, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "DEA", "Schedule I", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "DEA keeps all psychedelics in Schedule I without rescheduling by 2028", "plain_what": "Schedule I means the government treats a drug as having no medical value and high abuse risk \u2014 the harshest legal category. The DEA (which controls drug scheduling) almost never moves drugs to easier schedules on its own. Instead, it creates special exemptions letting researchers access Schedule I drugs for studies while keeping them illegal everywhere else. That's probably what will happen with psychedelics \u2014 not actual legalization, but research carve-outs." }, { "date": "2026-04-29", "title": "At least three additional U.S. states pass veteran-specific ibogaine access legislation by end of 2027", "confidence": 62, "category": "legislation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "ibogaine", "legislation", "veteran", "state law" ], "status": "pending", "priority": "high", "plain_title": "Three more states pass ibogaine access laws for veterans by end of 2027", "plain_what": "Texas already passed a law letting veterans use ibogaine outside clinical trials. Veterans are a sympathetic group, and states are willing to pass right-to-try laws giving people access to unproven treatments. But ibogaine causes serious heart problems, and state legislators will worry about liability \u2014 if someone dies from a heart attack after ibogaine their state approved, who gets sued? That worry will slow things down. Probably only three more states will do this by 2027." }, { "date": "2026-04-29", "title": "FDA issues formal protocol amendment guidance affecting active psychedelic clinical trials based on fluoxetine-psychedelic interaction data by Q2 2027", "confidence": 45, "category": "research", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "FDA", "SSRI", "drug-drug interaction", "psychedelics", "clinical trials" ], "status": "pending", "priority": "medium", "plain_title": "FDA issues protocol guidance on fluoxetine-psychedelic data by Q2 2027", "plain_what": "If scientists publish solid evidence that fluoxetine and psychedelics don't mix well, the FDA might put out official written guidance telling researchers how to handle this in clinical trials. But FDA guidance takes 18-36 months to write after the data comes out. For that to happen by mid-2027, the science would already need to be published and in FDA's hands by mid-2025. That timeline is tight and probably won't happen." }, { "date": "2026-04-30", "title": "MAPS or Compass Pathways publishes Phase 3 psilocybin trial enrollment or safety data update", "confidence": 80, "category": "research", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "high", "plain_title": "MAPS or Compass publishes psilocybin trial safety or enrollment update", "plain_what": "Two major psychedelic companies running government-approved depression trials must publicly share how their studies are going. This matters because it tells patients, doctors, and investors whether magic mushroom therapy actually works and is safe." }, { "date": "2026-04-30", "title": "DEA maintains Schedule I status for psilocybin and MDMA through October 2026 with no approved rescheduling petition", "confidence": 88, "category": "legislation", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "high", "plain_title": "DEA keeps psilocybin and MDMA illegal through October 2026", "plain_what": "The DEA (US drug enforcement agency) almost certainly will not change the legal status of magic mushrooms or MDMA in the next six months. That's because no approved medicine using these drugs exists yet, and rescheduling requires years of bureaucratic work." }, { "date": "2026-04-30", "title": "A bipartisan psychedelic research bill is introduced in the U.S. Congress", "confidence": 62, "category": "legislation", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Congress introduces a bipartisan bill supporting psychedelic research", "plain_what": "At least one member of Congress from each major party will sponsor a bill aimed at expanding research funding or removing regulatory barriers for psychedelics. Introducing a bill is easy; passing it is hard. This matters because it signals that politicians see this research as legitimate." }, { "date": "2026-04-30", "title": "At least one U.S. state legislature passes a psychedelic decriminalization or regulated therapeutic access bill", "confidence": 38, "category": "legislation", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "medium", "plain_title": "One US state passes a psychedelic therapy or decriminalization law", "plain_what": "A state legislature will vote and pass a bill allowing either regulated psilocybin therapy (like Oregon and Colorado did) or decriminalizing possession of psychedelics. This matters because it creates legal markets and proves the model works elsewhere. However, this is harder than just introducing a bill\u2014the law must actually pass both chambers and be signed." }, { "date": "2026-04-30", "title": "A U.S. insurer, CMS, or federal agency issues formal guidance or announces a pilot program for psychedelic-assisted therapy reimbursement", "confidence": 8, "category": "market", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "medium", "plain_title": "US insurer or Medicare announces psychedelic therapy reimbursement guidance", "plain_what": "CMS (Centers for Medicare and Medicaid Services, which runs Medicare) or a major insurance company announces they will pay for psilocybin or MDMA therapy. This would be huge for patients and companies. But it almost won't happen in six months because the FDA hasn't approved any psychedelic medicine yet, and insurers won't pay for unapproved drugs." }, { "date": "2026-04-30", "title": "A U.S. federal or state bill specifically addressing indigenous ceremonial plant medicine access or sovereignty is formally introduced", "confidence": 42, "category": "legislation", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "medium", "plain_title": "Congress introduces bill protecting Indigenous plant medicine and sovereignty rights", "plain_what": "A legislator will formally introduce a bill that protects Indigenous peoples' ability to use traditional plant medicines like peyote, ayahuasca, or psilocybin in ceremonies, and recognizes tribal sovereignty over these practices. This matters because it validates Indigenous knowledge and potentially carves out legal space for traditional healing. But federal bills on this are rare." }, { "date": "2026-04-30", "title": "MAPS or Compass Pathways publicly announces Phase 3 psilocybin efficacy data or a formal FDA pre-approval meeting", "confidence": 55, "category": "research", "geography": "USA", "resolve_date": "2026-10-30", "tags": [], "status": "pending", "priority": "high", "plain_title": "Compass or MAPS announces Phase 3 results or FDA pre-approval meeting", "plain_what": "One of the two leading companies will announce new data showing how well their psilocybin therapy works, or announce a formal meeting with the FDA to discuss approval. Compass already reported results; MAPS is earlier. Either company sharing next-step news matters because it moves closer to actual FDA approval." }, { "date": "2026-05-01", "title": "FDA will issue formal guidance requiring mandatory cardiac screening protocols (ECG, QTc thresholds) for any ibogaine IND by Q3 2026, effectively gatekeeping clinical access without blocking analog development.", "confidence": 62, "category": "regulation", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "ibogaine", "FDA" ], "status": "pending", "priority": "high", "plain_title": "FDA requires heart screening tests for ibogaine drug trials", "plain_what": "The FDA (the US drug regulator) will publish official rules saying anyone testing ibogaine in humans must do EKG heart tests first and check for dangerous heart rhythms. This matters because ibogaine can affect your heart, and regulators need to protect trial volunteers\u2014but the new rules won't stop companies from developing safer versions of ibogaine." }, { "date": "2026-05-01", "title": "At least two Phase 3 psychedelic trials will formally adopt standardized fluoxetine washout protocols (documented in trial registry or protocol amendment) by Q4 2026.", "confidence": 52, "category": "research", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "Phase 3", "fluoxetine", "washout" ], "status": "pending", "priority": "high", "plain_title": "Two major psilocybin trials will require patients to stop antidepressants", "plain_what": "Researchers running big psilocybin studies will update their rules to require people taking fluoxetine (Prozac) to stop the drug before the trial, and they'll document this in public trial databases. This matters because fluoxetine might interfere with psilocybin's effects, and trials need to show clean results." }, { "date": "2026-05-01", "title": "Oxa-noribogaine developers will achieve a sustained public market or disclosed private valuation premium of 40%+ over comparable raw ibogaine-focused companies within 12 months of 2026-05-01.", "confidence": 48, "category": "market", "geography": "Global", "resolve_date": "2027-05-01", "tags": [ "ibogaine", "oxa-noribogaine", "valuation" ], "status": "pending", "priority": "high", "plain_title": "Safer ibogaine versions will be worth much more than original", "plain_what": "Companies developing oxa-noribogaine (a safer chemical cousin of ibogaine) will be valued at least 40% higher than companies focusing only on raw ibogaine, within one year of May 2026. This matters to investors because it signals which version of the drug the market thinks will actually work and get approved." }, { "date": "2026-05-01", "title": "Fluoxetine washout standardization will be documented as adopted protocol practice across at least two Phase 3 psychedelic trials by 2026-07-30.", "confidence": 28, "category": "research", "geography": "USA", "resolve_date": "2026-07-30", "tags": [ "FDA", "Phase 3", "fluoxetine", "washout" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin trials will require antidepressant washout by July 2026", "plain_what": "At least two major psilocybin studies will update their trial rules to require fluoxetine washout and publish this change publicly by July 30, 2026. This is a tighter deadline than the previous prediction and matters because protocol changes usually take months to approve through review boards." }, { "date": "2026-05-01", "title": "FDA will formally request endpoint renegotiation or place a clinical hold on at least one active psilocybin or ibogaine addiction trial citing mismatch between extinction-enhancement mechanism and relapse-prevention primary endpoint by Q2 2027.", "confidence": 38, "category": "research", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "psilocybin", "ibogaine", "addiction", "FDA", "endpoints" ], "status": "pending", "priority": "high", "plain_title": "FDA may halt a psilocybin trial over treatment endpoint mismatch", "plain_what": "The FDA (US drug regulator) might put a clinical hold on or ask researchers to redesign at least one big psilocybin or ibogaine addiction trial because the main goal (stopping relapse) doesn't match how the drug actually works (helping people forget trauma). This matters because if the FDA thinks a trial is measuring the wrong thing, it can freeze the study until researchers fix it." }, { "date": "2026-05-02", "title": "Psychedelic biotech sector aggregate market cap will not recover to 2024 highs before 2026-09-30, absent an FDA approval or clear NDA acceptance for a psychedelic compound.", "confidence": 80, "category": "market", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "FDA", "biotech", "market" ], "status": "pending", "priority": "high", "plain_title": "Psychedelic biotech stocks won't recover to 2024 peaks by September 2026", "plain_what": "Psychedelic drug companies' stock prices fell sharply from their 2024 highs and haven't bounced back. Without an actual FDA approval or a clear sign that one is coming, investors see no reason to pour money back in. The sector needs real regulatory wins to recover." }, { "date": "2026-05-02", "title": "FDA will issue formal written guidance requiring cardiac monitoring protocols (including QT-interval surveillance) as a prerequisite for any ibogaine or ibogaine-analog IND submission, before 2027-01-15.", "confidence": 79, "category": "regulation", "geography": "USA", "resolve_date": "2027-01-15", "tags": [ "ibogaine", "FDA", "cardiac-safety" ], "status": "pending", "priority": "high", "plain_title": "FDA will mandate cardiac monitoring for ibogaine drug trials by January 2027", "plain_what": "Ibogaine, a plant medicine some people use for addiction, can affect the heart's electrical rhythm. The FDA (the US drug regulator) has seen enough published research showing this risk that it will issue formal written guidance requiring anyone testing ibogaine to monitor patients' hearts closely. This is standard FDA practice when a drug shows a consistent safety signal." }, { "date": "2026-05-02", "title": "No psychedelic compound will receive FDA approval or be federally rescheduled before 2026-12-31.", "confidence": 82, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "MDMA", "psilocybin", "ibogaine", "FDA", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug will be approved or rescheduled by end of 2026", "plain_what": "MDMA (the active ingredient in ecstasy) got rejected by the FDA in 2024 and needs more data before resubmission. Psilocybin (magic mushrooms' active compound) is years away from even applying for approval. Congress hasn't passed any bills to reschedule these drugs federally. Every pathway to approval or rescheduling hits a wall before 2027." }, { "date": "2026-05-02", "title": "Ibogaine cardiac safety literature will constitute a recognized regulatory signal sufficient to require mandatory cardiac monitoring protocols in any new IND submission for ibogaine or close analogs, delaying direct ibogaine clinical development timelines materially into 2027.", "confidence": 72, "category": "regulation", "geography": "Global", "resolve_date": "2026-07-31", "tags": [ "ibogaine", "cardiac-safety", "FDA", "clinical-trials" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine heart risk will force FDA to delay trials into 2027", "plain_what": "Ibogaine's risk to heart rhythm is now documented clearly enough in published research that the FDA will treat it as an official safety signal. This means anyone wanting to run an ibogaine trial will face mandatory cardiac monitoring requirements, which will delay trial startup and add costs. FDA precedent shows they respond this way to cardiac risks in new brain drugs." }, { "date": "2026-05-02", "title": "Psychedelic biotech equities will remain below 2024 high-water marks through 2026-09-30, with no sector-wide recovery absent a positive FDA binary event.", "confidence": 78, "category": "market", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "FDA", "biotech", "market" ], "status": "pending", "priority": "high", "plain_title": "Psychedelic biotech stocks will stay depressed through September 2026", "plain_what": "Multiple industry experts agree: psychedelic drug company stocks are down and won't recover until the FDA actually approves a drug or gives clear signals it will. Without real regulatory progress, the sector will languish. This prediction captures broad expert consensus on market dynamics." }, { "date": "2026-05-03", "title": "FDA will issue formal guidance requiring cardiac screening protocols as a precondition for ibogaine IND approval by Q1 2027.", "confidence": 52, "category": "regulation", "geography": "USA", "resolve_date": "2027-03-01", "tags": [ "ibogaine", "FDA" ], "status": "pending", "priority": "high", "plain_title": "FDA issues formal cardiac screening rules for ibogaine trials", "plain_what": "The FDA (the US drug regulator) will publish official written guidance saying that anyone testing ibogaine\u2014a plant-based psychedelic being studied for addiction\u2014must first get heart tests to check for dangerous electrical abnormalities. This matters because ibogaine can affect your heart rhythm, and the FDA needs to protect patients in clinical trials." }, { "date": "2026-05-03", "title": "Cardiac screening will be included as a mandatory requirement in at least one enacted or advanced federal ibogaine access bill or FDA guidance document by August 2026.", "confidence": 44, "category": "regulation", "geography": "USA", "resolve_date": "2026-08-01", "tags": [ "ibogaine", "legislation", "FDA" ], "status": "pending", "priority": "high", "plain_title": "Cardiac screening becomes mandatory in one federal ibogaine bill or guidance", "plain_what": "At least one official pathway to legal ibogaine\u2014either a law passed by Congress or an FDA (US drug regulator) rule\u2014will require heart screening before anyone can use it. This is a lower bar than FDA guidance alone: it could be a bill text, a proposed FDA rule, or a condition letter from the FDA to a specific company." }, { "date": "2026-05-03", "title": "Any federal ibogaine access legislation that passes both chambers will include mandatory cardiac screening as a statutory floor requirement.", "confidence": 71, "category": "legislation", "geography": "USA", "resolve_date": "2027-06-01", "tags": [ "ibogaine", "legislation" ], "status": "pending", "priority": "medium", "plain_title": "Any federal ibogaine law will require cardiac screening if it passes", "plain_what": "If Congress actually passes a law allowing ibogaine access\u2014something that hasn't happened yet and faces long odds\u2014that law almost certainly will require heart screening first. The logic is political: any law that didn't screen for cardiac risk would face fierce opposition, so any bill that survives both chambers will include it." }, { "date": "2026-05-03", "title": "MMED (Mind Medicine) share price will remain below its Q1 2026 high through September 30, 2026, absent a confirmed FDA catalyst event.", "confidence": 68, "category": "market", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "FDA", "biotech", "MMED" ], "status": "pending", "priority": "high", "plain_title": "Mind Medicine stock stays flat or down through September 2026", "plain_what": "Mind Medicine (ticker: MMED), a psychedelic drug company, will not recover to its highest price in early 2026 between now and the end of September 2026\u2014unless the FDA (the US drug regulator) approves one of their drugs or they announce successful late-stage trial results. Without good news from the FDA, the stock is likely to stay weak." }, { "date": "2026-05-03", "title": "The psychedelic biotech sector (as proxied by PSYK ETF or equivalent index) will show no positive return from May 2026 levels through June 2, 2026, absent a confirmed FDA approval or Phase 3 trial success announcement.", "confidence": 61, "category": "market", "geography": "USA", "resolve_date": "2026-06-02", "tags": [ "FDA", "biotech" ], "status": "pending", "priority": "medium", "plain_title": "Psychedelic biotech sector flat or down by early June 2026", "plain_what": "The psychedelic biotech sector\u2014tracked by the PSYK ETF (an exchange-traded fund that holds psychedelic drug companies)\u2014will show no gain from May through early June 2026 unless the FDA (the US drug regulator) approves a psychedelic drug or a company announces success in a late-stage trial. Over just 30 days, the sector is likely to stay stuck without major good news." }, { "date": "2026-05-03", "title": "Glutamatergic mPFC modulation will be cited as the primary mechanistic hypothesis for ibogaine-class therapeutic effects in the majority of new ibogaine/noribogaine preclinical publications by end of 2028.", "confidence": 48, "category": "research", "geography": "Global", "resolve_date": "2028-01-01", "tags": [ "ibogaine", "neuroscience", "mechanism" ], "status": "pending", "priority": "medium", "plain_title": "Ibogaine research shifts focus to brain chemistry pathway by 2028", "plain_what": "By the end of 2028, most new scientific papers studying how ibogaine works will focus on a specific brain circuit\u2014the mPFC (medial prefrontal cortex) and its glutamate chemistry\u2014rather than older theories about opioid receptors. This shift reflects cleaner scientific evidence and simpler explanations that drug companies prefer, though the field changes slowly." }, { "date": "2026-05-04", "title": "FDA will issue formal guidance specifically addressing cardiac monitoring requirements for ibogaine and ibogaine analog trials by Q2 2027.", "confidence": 52, "category": "regulation", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "ibogaine", "FDA", "cardiac safety" ], "status": "pending", "priority": "high", "plain_title": "FDA publishes heart-safety rules for ibogaine trials", "plain_what": "The FDA (the US drug regulator) will write down specific rules about how companies must monitor people's hearts during ibogaine trials. This matters because ibogaine can affect heart rhythm in ways that could be dangerous, and right now there are no clear federal rules about what doctors have to check." }, { "date": "2026-05-04", "title": "At least three published clinical trial protocol amendments for ongoing psilocybin or MDMA trials will cite SSRI/fluoxetine interaction data as justification for modified washout criteria by Q3 2026.", "confidence": 28, "category": "research", "geography": "Global", "resolve_date": "2026-09-30", "tags": [ "psilocybin", "MDMA", "SSRI", "clinical trial", "protocol amendment" ], "status": "pending", "priority": "high", "plain_title": "Trial protocols cite SSRI drug interaction research in washout rules", "plain_what": "Ongoing psilocybin and MDMA clinical trials will publicly announce changes to their rules about how long people must stop taking SSRIs (common antidepressants like Prozac) before entering the trial. They'll do this because new research shows these drugs interact with psychedelics in ways that matter for safety." }, { "date": "2026-05-04", "title": "SSRI washout protocols will be formally required (via FDA mandate or sponsor-initiated amendments across at least five active trials) for MDMA and psilocybin INDs by August 2026, causing measurable enrollment delays at multiple sites.", "confidence": 14, "category": "regulation", "geography": "Global", "resolve_date": "2026-08-02", "tags": [ "psilocybin", "MDMA", "SSRI", "FDA", "enrollment" ], "status": "pending", "priority": "medium", "plain_title": "SSRI washout rules mandated across multiple trials by mid-2026", "plain_what": "Within 18 months, the FDA (or major drug companies running trials) will require people to stop taking SSRIs for a set period before joining MDMA or psilocybin trials. This will slow down enrollment because fewer people will be eligible, and the waiting period will be longer." }, { "date": "2026-05-04", "title": "A serious adverse event at an unregulated U.S. ketamine or psychedelic clinic will be cited in congressional hearing testimony or trigger a formal federal investigation within 12 months of today.", "confidence": 38, "category": "safety", "geography": "USA", "resolve_date": "2027-05-04", "tags": [ "ketamine", "adverse event", "congressional oversight", "clinic safety" ], "status": "pending", "priority": "high", "plain_title": "Congressional hearing or federal probe triggered by ketamine clinic harm", "plain_what": "Someone will be seriously hurt or die at an unregulated ketamine or psychedelic clinic in the US, the story will get attention, and Congress or a federal agency will hold a public hearing or launch a formal investigation. This matters because ketamine clinics are booming but barely regulated, and one high-profile disaster could reshape the whole industry." }, { "date": "2026-05-04", "title": "FDA will issue formal guidance on QT monitoring requirements for ibogaine by mid-2027, and this guidance will be cited as a primary reason for delay in at least one IND progress report filed before December 2027.", "confidence": 31, "category": "regulation", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "ibogaine", "FDA", "cardiac safety", "IND" ], "status": "pending", "priority": "medium", "plain_title": "FDA heart-safety guidance delays at least one ibogaine IND approval", "plain_what": "The FDA will publish formal rules about heart monitoring for ibogaine, and at least one company running an ibogaine trial will later tell the FDA that this new guidance is the reason their trial got delayed. This is similar to the first prediction but focuses on whether the new rules actually slow down drug approvals." }, { "date": "2026-05-05", "title": "No standalone federal psychedelic scheduling bill will pass both chambers before the 2026 midterms.", "confidence": 90, "category": "legislation", "geography": "USA", "resolve_date": "2026-11-03", "tags": [ "legislation", "scheduling", "psychedelics" ], "status": "pending", "priority": "high", "plain_title": "Congress won't pass a standalone psychedelic bill before mid-2026", "plain_what": "Right now, Congress has no psychedelic scheduling bills scheduled for a real hearing. The DEA (Drug Enforcement Administration) opposes them. With fewer than 15 weeks of actual legislative time left before the November 2026 elections, a standalone bill has almost no chance\u2014the only realistic path would be sneaking it into a larger military spending bill or budget bill." }, { "date": "2026-05-05", "title": "FDA will issue formal written guidance requiring mandatory cardiac screening (ECG, QTc baseline) for any ibogaine IND submitted or amended in 2026.", "confidence": 62, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac", "IND" ], "status": "pending", "priority": "high", "plain_title": "FDA will require heart screening before testing ibogaine in humans", "plain_what": "Ibogaine (a plant-derived drug being tested for addiction) can damage the heart in serious ways\u2014the data is public and clear. The FDA (US drug regulator) will almost certainly demand that any company testing ibogaine in humans first does heart screening tests (an ECG baseline and QTc measurement) before those humans start the drug. This protects patients and shields the FDA from liability." }, { "date": "2026-05-05", "title": "DEA will submit formal written opposition to any NDAA provision creating ibogaine veteran access that bypasses Schedule I review, before December 31 2026.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "DEA", "Schedule I", "veteran", "NDAA" ], "status": "pending", "priority": "high", "plain_title": "DEA will formally oppose any law letting veterans skip ibogaine review", "plain_what": "Some in Congress want to create a fast track for military veterans to access ibogaine without waiting for Schedule I review (the formal drug classification process). The DEA has legal standing and institutional reasons to block this\u2014they will write an official letter or Congressional statement opposing any law that lets ibogaine bypass the normal review process." }, { "date": "2026-05-05", "title": "By November 2026, at least one major ibogaine clinical-stage company or academic program will publicly announce a pivot toward non-cardiotoxic ibogaine analogs (e.g., oxa-noribogaine) as their primary development candidate.", "confidence": 58, "category": "research", "geography": "Global", "resolve_date": "2026-11-05", "tags": [ "ibogaine", "oxa-noribogaine", "analogs", "cardiac", "drug-development" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine companies will publicly switch to safer chemical alternatives", "plain_what": "Ibogaine works for some addictions but harms the heart. Companies and researchers testing ibogaine know this. By November 2026, at least one major company or academic lab will publicly announce they're shifting their main focus to safer versions\u2014like oxa-noribogaine, a chemical cousin without the heart damage. They'll say this out loud in a press release or research announcement because the cardiac risk makes ibogaine hard to sell to regulators and patients." }, { "date": "2026-05-05", "title": "At least two additional U.S. states will formally introduce legislation establishing veteran-specific psychedelic therapy access programs in calendar year 2026.", "confidence": 78, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "veteran", "state-legislation", "psychedelics", "psilocybin", "ketamine" ], "status": "pending", "priority": "high", "plain_title": "Two more states will propose veteran psychedelic therapy access laws in 2026", "plain_what": "States like Texas, Colorado, Oregon, and Arizona are already moving ahead with their own psychedelic therapy programs\u2014they don't wait for the federal government. By the end of 2026, at least two additional states will formally introduce (file) new bills creating veteran-only psychedelic therapy programs. This counts bills filed, even if they don't pass, because state-level momentum is real and separate from federal drug scheduling." }, { "date": "2026-05-06", "title": "At least one psychedelic compound \u2014 most likely COMPASS Pathways COMP360 \u2014 will receive FDA approval or formal approval recommendation before end of 2027.", "confidence": 87, "category": "regulation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "FDA", "COMPASS", "COMP360", "psilocybin", "TRD", "approval" ], "status": "pending", "priority": "critical", "plain_title": "First psychedelic drug approved by FDA by end of 2027", "plain_what": "COMPASS Pathways' psilocybin compound COMP360 is on track to become the first psychedelic drug approved by the FDA, likely for treatment-resistant depression \u2014 meaning millions of people who don't respond to antidepressants would have a new legal option." }, { "date": "2026-05-06", "title": "Trump EO Right to Try pathway will produce at least one operational psychedelic patient access program before January 2027.", "confidence": 79, "category": "regulation", "geography": "USA", "resolve_date": "2027-01-01", "tags": [ "Right_to_Try", "ibogaine", "psilocybin", "Texas", "patient_access", "EO" ], "status": "pending", "priority": "high", "plain_title": "Legal psychedelic therapy access program opens in the US before 2027", "plain_what": "The Trump executive order created a pathway for seriously ill patients to access investigational psychedelic drugs \u2014 and Texas is moving fastest to build the first operational program." }, { "date": "2026-05-06", "title": "DEA will formally initiate rescheduling review for at least one psychedelic compound before April 2027.", "confidence": 71, "category": "legislation", "geography": "USA", "resolve_date": "2027-04-18", "tags": [ "DEA", "rescheduling", "Schedule_I", "psilocybin", "EO" ], "status": "pending", "priority": "high", "plain_title": "DEA begins formal process to move psilocybin out of Schedule I", "plain_what": "The DEA will start the legal process to reclassify psilocybin from Schedule I (most dangerous, no accepted medical use) to a lower schedule \u2014 a historic step that would make it legal to prescribe and manufacture." }, { "date": "2026-05-06", "title": "Psychedelic biotech sector will trade higher 6 months post-EO (October 2026) versus pre-EO (April 17, 2026).", "confidence": 83, "category": "market", "geography": "Global", "resolve_date": "2026-10-18", "tags": [ "CMPS", "ATAI", "stocks", "market", "investors", "sector" ], "status": "pending", "priority": "high", "plain_title": "Psychedelic stocks will be higher in October than they were before Trump's order", "plain_what": "The cluster of psychedelic drug companies \u2014 COMPASS Pathways, AtaiBeckley, Mind Medicine, others \u2014 has already surged on the executive order and will likely be trading even higher by October as FDA decision timelines approach." }, { "date": "2026-05-06", "title": "Major pharma company will announce licensing, acquisition or partnership with psychedelic biotech before January 2027.", "confidence": 62, "category": "market", "geography": "Global", "resolve_date": "2027-01-01", "tags": [ "BigPharma", "acquisition", "licensing", "partnership", "consolidation" ], "status": "pending", "priority": "medium", "plain_title": "A major drug company will buy or partner with a psychedelic biotech this year", "plain_what": "One of the world's largest pharmaceutical companies \u2014 Pfizer, J&J, Eli Lilly, Roche, or similar \u2014 will likely announce a deal with a psychedelic drug company before the year is out, following the same playbook used with gene therapy and GLP-1 drugs." }, { "date": "2026-05-06", "title": "Microdosing will see at least 5 new FDA-approved IND applications filed before December 2026.", "confidence": 91, "category": "research", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "microdosing", "IND", "clinical_trials", "FDA", "scalability" ], "status": "pending", "priority": "medium", "plain_title": "Microdosing becomes the fastest-growing psychedelic research area in 2026", "plain_what": "Small, sub-perceptual doses of psychedelics (microdosing) are becoming the next big clinical research area because they don't require expensive therapist sessions \u2014 making them easier to prescribe and scale." }, { "date": "2026-05-06", "title": "UC system (UCSF, UCLA, UCSD) will publish statistically significant psilocybin results in a non-psychiatric indication before December 2027.", "confidence": 76, "category": "research", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "UCSF", "UCLA", "UCSD", "psilocybin", "chronic_pain", "burnout", "expansion" ], "status": "pending", "priority": "medium", "plain_title": "Psilocybin shown to work for something beyond depression or PTSD", "plain_what": "University of California researchers are testing psilocybin for chronic back pain, eating disorders, and doctor burnout \u2014 and one of these trials is expected to show significant positive results before 2028." }, { "date": "2026-05-06", "title": "Psychedelic-assisted therapy will be standard in psychiatric training programs by January 2028.", "confidence": 94, "category": "culture", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "psychiatry", "training", "curriculum", "mainstream", "culture_shift" ], "status": "pending", "priority": "medium", "plain_title": "Medical schools will teach psychedelic therapy as standard psychiatry by 2028", "plain_what": "Within the next 18 months, psychiatry residents, nurses, and mental health practitioners will be studying psychedelic-assisted therapy as a required part of their medical training \u2014 not a fringe elective." }, { "date": "2026-05-06", "title": "Psychedelic field will achieve formal bipartisan Congressional recognition before end of 2026.", "confidence": 88, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "Congress", "bipartisan", "veterans", "legislation", "hearings" ], "status": "pending", "priority": "medium", "plain_title": "Both parties in Congress will formally acknowledge psychedelic therapy as legitimate medicine by end of 2026", "plain_what": "Congress will hold a formal hearing or pass resolution language officially recognizing psychedelic therapy \u2014 ending the political stigma that has blocked legislation for decades." }, { "date": "2026-05-07", "title": "No federal rescheduling of any classical psychedelic \u2014 psilocybin, MDMA, LSD, DMT \u2014 will occur before 2028.", "confidence": 85, "category": "legislation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "psilocybin", "MDMA", "DMT", "LSD", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic rescheduling at federal level before 2028", "plain_what": "The federal government won't move psilocybin, MDMA, LSD, or DMT from Schedule I (the strictest category) to a lower schedule before 2028. This matters because rescheduling is the only legal path that lets doctors prescribe these drugs widely \u2014 and it requires the FDA to first approve one as a medicine, which hasn't happened yet." }, { "date": "2026-05-07", "title": "Federal psilocybin scheduling reform will not receive a floor vote in the 119th Congress (ending January 3, 2027).", "confidence": 87, "category": "legislation", "geography": "USA", "resolve_date": "2027-01-03", "tags": [ "psilocybin", "rescheduling", "Congress" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin rescheduling won't get a Congressional vote by January 2027", "plain_what": "Congress (specifically the House or Senate) won't vote on a psilocybin rescheduling bill before January 3, 2027, when the current Congress ends. No bill has made it out of committee, and party leaders aren't pushing it as a priority. A small bipartisan group of members supports it, but they don't have the votes or the political machinery to force a floor vote." }, { "date": "2026-05-07", "title": "FDA will issue a formal clinical hold or safety guidance on at least one ibogaine IND citing QT prolongation before end of 2026.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "clinical-hold", "cardiac" ], "status": "pending", "priority": "high", "plain_title": "FDA will warn about ibogaine heart rhythm dangers by end of 2026", "plain_what": "The FDA will formally halt or restrict at least one ibogaine drug trial (called a clinical hold) or issue safety guidance because of a cardiac problem called QT prolongation \u2014 a heartbeat irregularity that can cause sudden death. Ibogaine is known to affect the heart's electrical system, and researchers have already documented this risk in peer-reviewed studies. The FDA uses this evidence to trigger safety holds." }, { "date": "2026-05-07", "title": "Ibogaine cardiac safety will remain the primary regulatory gating factor for all FDA and Congressional ibogaine progress through at least mid-2027.", "confidence": 78, "category": "regulatory", "geography": "USA", "resolve_date": "2027-07-01", "tags": [ "ibogaine", "FDA", "cardiac", "regulation" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine heart safety will block FDA progress through mid-2027", "plain_what": "The cardiac (heart) safety problem with ibogaine \u2014 specifically QT prolongation \u2014 will be the main reason the FDA doesn't approve ibogaine or clear new trials for at least 18 more months. No new research has emerged to prove the heart risk is safe or manageable, so the safety concern stays locked in place as the blocking point. Ibogaine advocates are pushing, but the FDA won't move until the heart problem is resolved." }, { "date": "2026-05-07", "title": "FDA will not publish a formal guidance document on SSRI-psychedelic washout protocols before November 2027.", "confidence": 70, "category": "regulatory", "geography": "USA", "resolve_date": "2027-11-07", "tags": [ "FDA", "SSRI", "psilocybin", "MDMA", "trial-design" ], "status": "pending", "priority": "medium", "plain_title": "FDA won't publish SSRI-psychedelic interaction guidance by November 2027", "plain_what": "The FDA won't issue official written instructions for doctors on how long patients taking SSRI antidepressants need to wait before using psychedelic medicines. Animal studies hint at an interaction risk, but the FDA needs human trial data to write guidance \u2014 and that data doesn't exist. FDA guidance documents take 12\u201324 months to write and approve internally, plus they need public comment periods. Official guidance won't land before November 2027." }, { "date": "2026-05-08", "title": "DEA will initiate formal scheduling review proceedings for psilocybin within 6 months of any FDA approval recommendation, extending access timelines by minimum 18 months", "confidence": 78, "category": "regulation", "geography": "USA", "resolve_date": "2028-06-01", "tags": [ "psilocybin", "FDA", "DEA" ], "status": "pending", "priority": "high", "plain_title": "DEA delays psilocybin access by 18+ months after any FDA approval", "plain_what": "The DEA (Drug Enforcement Administration\u2014the federal agency that classifies illegal drugs) has its own separate legal power to review and approve drugs, independent of the FDA (the US drug regulator). If the FDA approves psilocybin for medical use, the DEA will launch its own formal review that typically takes 18+ months to complete. This matters because patients and researchers have to wait even after the FDA says yes." }, { "date": "2026-05-08", "title": "FDA will issue a formal ibogaine cardiac safety guidance document requiring mandatory QT monitoring protocols before any IND expansion, slowing veteran access trials by 12-18 months", "confidence": 75, "category": "regulation", "geography": "USA", "resolve_date": "2027-03-01", "tags": [ "ibogaine", "FDA", "veteran" ], "status": "pending", "priority": "high", "plain_title": "FDA mandates heart monitoring for ibogaine, delaying veteran therapy access", "plain_what": "Ibogaine (a plant-derived compound) causes a known heart rhythm problem called QT prolongation\u2014the time it takes your heart's electrical system to reset after each beat. The FDA has documented adverse events and will require mandatory EKG (heart monitoring) before patients can receive ibogaine in clinical trials. This adds 12\u201318 months to the timeline because the FDA has to write new safety rules, and study teams have to redesign their protocols to include the monitoring." }, { "date": "2026-05-08", "title": "Federal rescheduling of any classical psychedelic will not occur before 2028, due to DEA independent scheduling process adding 18-24 months beyond any FDA action", "confidence": 80, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "FDA", "DEA", "psilocybin", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "No classical psychedelic will be rescheduled federally before 2028", "plain_what": "Classical psychedelics like psilocybin, LSD, and mescaline are illegal Schedule I drugs (meaning the DEA says they have no medical use). Rescheduling means moving them to a lower schedule so doctors can prescribe them. The FDA and DEA both have to approve this, and the whole process\u2014from an FDA recommendation to final DEA approval\u2014takes 18\u201324 months. No psychedelic company has filed the paperwork for FDA approval yet, so the earliest an FDA recommendation could come is 2026\u20132027, making 2028 the earliest possible rescheduling date." }, { "date": "2026-05-08", "title": "A documented serious adverse event at a commercial psychedelic retreat will receive major national media coverage before end of 2026, triggering emergency state-level regulatory review in Oregon or Colorado", "confidence": 62, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "Oregon", "Colorado", "retreat", "safety" ], "status": "pending", "priority": "high", "plain_title": "A serious retreat injury will trigger state-level safety crackdowns by 2026", "plain_what": "Oregon and Colorado now allow licensed psychedelic retreat centers to operate legally. These programs are expanding fast, but safety standards vary widely between operators. A documented serious injury or death at one of these commercial retreats is likely to get major newspaper and TV coverage. When that happens, state regulators will launch emergency reviews and probably create stricter safety rules. This matters because it could slow down the entire industry's growth and change how these businesses operate." }, { "date": "2026-05-08", "title": "Ibogaine cardiac safety documentation will drive regulatory and investment bifurcation between natural ibogaine (restricted, mandatory monitoring) and synthetic analogs (accelerated development), with distinct treatment pathways formalized in FDA guidance or legislation by end of 2027", "confidence": 55, "category": "regulation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "ibogaine", "FDA", "legislation", "analogs" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine splits into two paths: natural (restricted) and synthetic (faster approval)", "plain_what": "Ibogaine causes heart rhythm problems that synthetic versions of the same molecule (or chemically similar compounds) may not cause. The FDA and investment companies are noticing this and moving toward a two-track approach: natural ibogaine gets heavy restrictions and mandatory heart monitoring, while new synthetic versions developed in labs get faster approval because they don't carry the same cardiac risk. By 2027, this split will probably be formalized in FDA guidance or new laws. This matters because it means natural ibogaine stays harder to access, while synthetic alternatives move faster toward patients." }, { "date": "2026-05-09", "title": "FDA will issue a formal Safety Communication or draft guidance specifically addressing ibogaine cardiac monitoring requirements before December 31, 2026.", "confidence": 62, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac-safety" ], "status": "pending", "priority": "high", "plain_title": "FDA issues formal safety alert on ibogaine heart monitoring by end of 2026", "plain_what": "The FDA (US drug regulator) will publish an official warning or guidance document about heart safety risks from ibogaine, a psychedelic compound being tested as a treatment. Two recent scientific papers documented heart rhythm problems in ibogaine users, which triggers an FDA obligation to communicate these risks publicly to doctors and patients." }, { "date": "2026-05-09", "title": "Ibogaine cardiac safety will become a formal regulatory bottleneck \u2014 via FDA IND hold letters, draft guidance, or DEA opposition \u2014 before December 31, 2026, forcing sponsors toward analog development or stricter protocol constraints.", "confidence": 71, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "DEA", "cardiac-safety" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine development stalls due to cardiac safety concerns and regulatory blocks", "plain_what": "Ibogaine drug trials will hit regulatory roadblocks \u2014 either the FDA (US drug regulator) will freeze trials pending better heart safety data, or the DEA (US drug enforcement agency) will block rescheduling efforts \u2014 before the end of 2026. These aren't obstacles that can be ignored; they force companies to redesign trials or develop chemically similar alternatives." }, { "date": "2026-05-09", "title": "DEA will formally oppose or delay any pending ibogaine rescheduling petition before December 31, 2026, citing cardiovascular adverse event literature published in 2026.", "confidence": 41, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "DEA", "Schedule-I", "rescheduling" ], "status": "pending", "priority": "medium", "plain_title": "DEA blocks ibogaine rescheduling using new cardiac safety evidence by 2026", "plain_what": "If someone files an official petition to move ibogaine from Schedule I (banned) to a looser category, the DEA (US drug enforcement agency) will reject it by citing the new heart safety papers published in 2026. This prediction only matters if a petition actually gets filed first \u2014 as of now, none is publicly confirmed." }, { "date": "2026-05-09", "title": "At least two pharmaceutical sponsors will file new INDs or major trial amendments targeting psilocybin for cocaine use disorder before December 31, 2026.", "confidence": 52, "category": "research", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "cocaine-use-disorder", "IND", "clinical-trials" ], "status": "pending", "priority": "high", "plain_title": "Two major companies file new psilocybin trials for cocaine addiction by 2026", "plain_what": "A successful clinical trial published in a major scientific journal will show psilocybin helps people quit cocaine. This result will prompt at least two pharmaceutical companies (like COMPASS Pathways or ATAI Life Sciences) to file new Investigational New Drug applications (INDs \u2014 official permission to run human trials) or expand their existing trials. This matters because it opens a new market for psychedelic treatments beyond depression and anxiety." }, { "date": "2026-05-09", "title": "Psilocybin for cocaine use disorder will emerge as a named pipeline indication with at least two new IND filings or primary-endpoint trial amendments documented before August 7, 2026.", "confidence": 18, "category": "research", "geography": "Global", "resolve_date": "2026-08-07", "tags": [ "psilocybin", "cocaine-use-disorder", "IND" ], "status": "pending", "priority": "medium", "plain_title": "Two psilocybin cocaine addiction trials launch within three months", "plain_what": "This prediction says the same thing as the previous one but demands it happens within just 90 days (by August 7, 2026). That's an unrealistically tight timeline: preparing an IND application typically takes 6 months on its own. Even if a major trial publishes tomorrow, companies won't have filed two new INDs in three months." }, { "date": "2026-05-10", "title": "FDA will issue a formal ibogaine safety communication or guidance document citing cardiac risk before issuing any IND pathway expansion, effectively adding 12-18 months to regulatory timeline.", "confidence": 72, "category": "regulatory", "geography": "USA", "resolve_date": "2027-03-01", "tags": [ "ibogaine", "FDA", "cardiac", "IND" ], "status": "pending", "priority": "high", "plain_title": "FDA issues cardiac safety warning on ibogaine, delaying approval 12\u201318 months", "plain_what": "The FDA (the US drug regulator) will publicly release a formal safety alert about ibogaine's risk of irregular heartbeats before allowing clinical trials to expand. This happens because the drug causes a measurable change in heart electrical activity called QT prolongation. The delay matters because it pushes any potential approval years further away." }, { "date": "2026-05-10", "title": "Any viable ibogaine NDA pathway will formally require a mandatory cardiac monitoring protocol, making 2028 the earliest realistic federal approval date.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2028-12-31", "tags": [ "ibogaine", "FDA", "NDA", "cardiac monitoring" ], "status": "pending", "priority": "high", "plain_title": "Any approved ibogaine treatment will require mandatory heart monitoring, approval by 2028", "plain_what": "If ibogaine ever gets approved by the FDA for medical use, the agency will require mandatory cardiac monitoring (likely EKGs and blood work) as part of its Risk Evaluation and Mitigation Strategy (REMS) \u2014 a framework the FDA uses to manage drugs with serious safety risks. This requirement will mean the earliest realistic approval date is late 2028." }, { "date": "2026-05-10", "title": "At least one U.S. state (most likely California) will operationalize a regulated psilocybin access framework with licensed facilitators before any federal scheduling change, creating a de facto two-tier system.", "confidence": 78, "category": "legislation", "geography": "USA", "resolve_date": "2026-11-06", "tags": [ "psilocybin", "legislation", "California", "state policy", "two-tier system" ], "status": "pending", "priority": "high", "plain_title": "States will open legal psilocybin therapy programs before federal law changes", "plain_what": "At least one US state\u2014probably California\u2014will create a legal, regulated system for psilocybin therapy with trained facilitators before the federal government reclassifies psilocybin (which takes years and faces opposition). This means people in those states can access psilocybin legally while it remains illegal federally, creating a two-tier system: some states allow it, the federal government doesn't." }, { "date": "2026-05-10", "title": "FDA will require at least one independent replication of psilocybin RCT data for cocaine use disorder before considering it label-worthy, making 2029 the earliest realistic approval date for that indication.", "confidence": 76, "category": "regulatory", "geography": "USA", "resolve_date": "2029-01-01", "tags": [ "psilocybin", "FDA", "cocaine use disorder", "RCT", "replication" ], "status": "pending", "priority": "high", "plain_title": "FDA will demand repeat studies of psilocybin for cocaine addiction, approval by 2029", "plain_what": "The FDA (the US drug regulator) will not approve psilocybin for treating cocaine addiction based on a single clinical trial. Instead, the agency will require independent researchers to replicate the results in a second study before it considers the drug effective enough. No completed Phase 3 trials (the gold-standard final stage) exist yet, so this means approval can't happen before 2029 at the earliest." }, { "date": "2026-05-10", "title": "California will enact legislation establishing a regulated psilocybin therapy framework with a licensed facilitator model before end of 2026.", "confidence": 52, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "California", "legislation", "facilitator model" ], "status": "pending", "priority": "high", "plain_title": "California passes legal psilocybin therapy law before end of 2026", "plain_what": "California will pass legislation that allows licensed therapists or facilitators to legally administer psilocybin in a regulated, medically supervised setting before December 2026. Similar programs already exist in Oregon and Colorado. California has active bills pending, though the governor vetoed a related psilocybin bill in 2023, creating some uncertainty about whether this specific law passes soon." }, { "date": "2026-05-10", "title": "A veteran death in an unregulated foreign ibogaine setting, with documented prior VA system contact, will trigger a formal U.S. Congressional hearing on ibogaine safety and access before end of 2026.", "confidence": 48, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "veterans", "Congress", "safety", "hearing" ], "status": "pending", "priority": "high", "plain_title": "Congressional hearing triggered by veteran death in unregulated ibogaine treatment", "plain_what": "A veteran (someone who served in the military) who died in an unsafe, unregulated ibogaine treatment facility abroad will create a news story that forces Congress to hold a public hearing about ibogaine safety and access. Thousands of veterans are traveling to foreign countries for ibogaine treatment annually because it's not available or illegal in the US, and deaths in unregulated settings do occur. The delay here is that this needs to happen in the next ~7 months with enough media attention to trigger congressional action." }, { "date": "2026-05-11", "title": "Veteran-led psychedelic retreat networks will serve over 5,000 veterans in informal settings by end of 2026.", "confidence": 55, "category": "culture", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "veteran", "psychedelics", "informal-access" ], "status": "pending", "priority": "medium", "plain_title": "Veterans will access psychedelic retreats outside the US by 5,000 by late 2026", "plain_what": "Groups like Heroic Hearts already run informal psychedelic retreats for military veterans in countries where these substances are legal or tolerated. The prediction says 5,000 veterans total will have used these retreats by the end of 2026. This matters because veterans struggle with PTSD and trauma, and some find relief through these retreats \u2014 but they happen in legal gray zones with no oversight." }, { "date": "2026-05-11", "title": "FDA will issue a formal safety communication specifically on ibogaine cardiac risks by 2027-02-11.", "confidence": 52, "category": "regulatory", "geography": "USA", "resolve_date": "2027-02-11", "tags": [ "ibogaine", "FDA", "cardiac-safety" ], "status": "pending", "priority": "high", "plain_title": "FDA will formally warn about ibogaine heart rhythm dangers by February 2027", "plain_what": "Ibogaine is a powerful plant medicine used to treat addiction, but it can disrupt your heart's electrical system and cause dangerous arrhythmias (irregular heartbeats). The FDA (the US drug regulator) publishes formal safety warnings when enough bad cases pile up. This prediction says they'll do that for ibogaine by early 2027. If they do, it will make any legal access to ibogaine much harder and signal serious risk." }, { "date": "2026-05-11", "title": "Ibogaine will face a formal FDA or DEA safety communication within 12 months (by 2026-08-09) that materially constrains any U.S. access expansion before 2028.", "confidence": 28, "category": "regulatory", "geography": "USA", "resolve_date": "2026-08-09", "tags": [ "ibogaine", "FDA", "DEA", "regulatory-barrier" ], "status": "pending", "priority": "high", "plain_title": "FDA or DEA will restrict ibogaine access before it expands in the US", "plain_what": "This is a shorter deadline version of the previous prediction \u2014 it asks whether regulators will formally constrain ibogaine before the end of summer 2026 (only three months away). The logic is the same: cardiac risks are piling up, but a formal warning this fast is unlikely unless something bad happens suddenly. Most federal agencies move slower than this." }, { "date": "2026-05-11", "title": "The extinction-without-relapse dissociation observed in psilocybin-cocaine studies will generate at least 3 competing mechanistic hypotheses in peer-reviewed literature within 12 months.", "confidence": 72, "category": "research", "geography": "Global", "resolve_date": "2027-05-11", "tags": [ "psilocybin", "cocaine", "mechanistic-debate", "addiction" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin research will spawn three competing theories about extinction without relapse", "plain_what": "Recent studies show psilocybin can help people quit cocaine by actually changing how the brain processes memory and reward \u2014 specifically, it breaks the link between cues and craving while leaving extinction memory intact. This is a weird dissociation that doesn't match current theory. The prediction says scientists will propose at least three different mechanistic explanations for this in peer-reviewed papers within a year. This matters because whoever figures it out right could design better addiction treatments." }, { "date": "2026-05-11", "title": "At least 4 new U.S. state bills legalizing or decriminalizing psychedelic therapy will pass by 2026-11-07, while no federal psychedelic therapy legislation advances past committee.", "confidence": 70, "category": "legislation", "geography": "USA", "resolve_date": "2026-11-07", "tags": [ "legislation", "state-policy", "psychedelics", "federal-stall" ], "status": "pending", "priority": "high", "plain_title": "US states will pass four new psychedelic therapy laws while Congress stays frozen", "plain_what": "Colorado and Oregon already have legal psychedelic therapy programs running. Minnesota, Massachusetts, California, Vermont and others are actively writing new bills right now. The prediction says at least four more states will pass laws legalizing or decriminalizing psychedelic-assisted therapy by November 2026, while Congress (the federal government) does nothing. This matters because it creates a patchwork of legal access across the country while the FDA and DEA remain unchanged." }, { "date": "2026-05-12", "title": "The psilocybin cocaine RCT will be widely misreported as a 'cure for addiction' in at least 3 major mainstream outlets, followed by a published correction or debunking piece within 60 days of initial coverage.", "confidence": 72, "category": "culture", "geography": "Global", "resolve_date": "2026-07-12", "tags": [ "psilocybin", "addiction", "media" ], "status": "pending", "priority": "high", "plain_title": "Media will hype psilocybin cocaine study as 'cure,' then print corrections", "plain_what": "When researchers publish findings on psilocybin helping people quit cocaine, news outlets will simplify the story into a flashy 'miracle cure' headline. Scientists and journalists will then have to publish corrections explaining the actual nuances. This happens because headlines need to be short and exciting, while the real science is complicated." }, { "date": "2026-05-12", "title": "FDA will issue a formal Safety Communication specifically on ibogaine-associated cardiac risks (QT prolongation/arrhythmia) before December 31, 2026.", "confidence": 38, "category": "regulation", "geography": "USA", "resolve_date": "2026-11-30", "tags": [ "ibogaine", "FDA", "cardiac" ], "status": "pending", "priority": "high", "plain_title": "FDA warns the public about ibogaine heart rhythm dangers", "plain_what": "The FDA (the U.S. drug regulator) will publish an official warning about ibogaine's documented risk of causing dangerous heart rhythm problems. This matters because people are seeking ibogaine treatment overseas for PTSD and addiction, but the FDA hasn't yet formally warned Americans about the specific cardiac danger, even though deaths have been documented." }, { "date": "2026-05-12", "title": "FDA will issue a formal Safety Communication on ibogaine cardiac risks before August 10, 2026, and this will create a measurable regulatory divergence in IND approval timelines between natural ibogaine and synthetic analogue (e.g., tabernanthalog, TBG) applications.", "confidence": 28, "category": "regulation", "geography": "USA", "resolve_date": "2026-08-10", "tags": [ "ibogaine", "FDA", "synthetic", "IND" ], "status": "pending", "priority": "high", "plain_title": "FDA cardiac warning on ibogaine causes split in synthetic drug approval", "plain_what": "The FDA will issue a cardiac safety warning about natural ibogaine, and this will push regulators to treat synthetic versions (engineered in labs to remove cardiac risk) differently\u2014approving or moving faster on the engineered versions while slowing natural ibogaine development. This creates a two-track system where the natural compound and its engineered cousins follow different FDA pathways." }, { "date": "2026-05-12", "title": "At least one U.S. Congressional committee will hold a public hearing specifically addressing FDA policy on ibogaine (including access, scheduling, or clinical trial pathways) before March 31, 2027.", "confidence": 55, "category": "legislation", "geography": "USA", "resolve_date": "2027-03-31", "tags": [ "ibogaine", "FDA", "veteran", "Congress" ], "status": "pending", "priority": "high", "plain_title": "Congress holds public hearing on FDA's ibogaine policy and access", "plain_what": "A U.S. Congressional committee will hold a public hearing asking the FDA to defend why Americans can't easily access ibogaine treatment, especially for veterans with PTSD and addiction. This matters because veterans are dying while accessing ibogaine overseas, creating political pressure for Congress to investigate regulatory roadblocks." }, { "date": "2026-05-12", "title": "At least one pre-registered multi-site replication trial of psilocybin's extinction-without-relapse-prevention mechanism in substance use disorder will be launched (registered on ClinicalTrials.gov or equivalent) before June 30, 2027.", "confidence": 52, "category": "research", "geography": "Global", "resolve_date": "2027-06-30", "tags": [ "psilocybin", "addiction", "clinical-trial", "replication" ], "status": "pending", "priority": "high", "plain_title": "Research team launches new psilocybin addiction study with clear science", "plain_what": "Scientists will register a new multi-site research study (publicly announced on ClinicalTrials.gov, the official trial registry) focused on understanding exactly how psilocybin helps people stop using cocaine or opioids. They'll pre-register their methods to prevent researchers from changing their approach after seeing results. This matters because it builds solid science on the mechanism (the actual biological how) rather than just whether it works." }, { "date": "2026-05-13", "title": "DEA will formally oppose any rescheduling petition for ibogaine before 2028, citing cardiac liability literature as sufficient scientific basis for continued Schedule I classification.", "confidence": 68, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "ibogaine", "DEA", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "DEA will formally reject any ibogaine rescheduling request by 2028", "plain_what": "The DEA (the US agency that controls which drugs are legal) will write an official letter saying no to any attempt to move ibogaine to a less restricted category. They'll point to medical studies showing the drug can damage the heart as their reason. This matters because it locks ibogaine out of legal medical use for years." }, { "date": "2026-05-13", "title": "No federal psychedelic scheduling reform legislation will reach a floor vote in either the House or Senate before November 2028.", "confidence": 78, "category": "legislation", "geography": "USA", "resolve_date": "2028-11-01", "tags": [ "ibogaine", "psychedelics", "scheduling reform" ], "status": "pending", "priority": "high", "plain_title": "No federal psychedelic law reform will reach a floor vote by end of 2028", "plain_what": "Congress won't bring any bill that loosens psychedelic drug rules to a formal floor vote in either the House or Senate before November 2028. Bills die quietly in committee because lawmakers and leadership haven't prioritized the issue, and new heart-safety data gives opponents ammunition to block progress." }, { "date": "2026-05-13", "title": "FDA will issue a formal safety communication or guidance document specifically addressing ibogaine cardiac risk before end of 2026.", "confidence": 42, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac safety" ], "status": "pending", "priority": "high", "plain_title": "FDA will issue a cardiac safety warning on ibogaine by end of 2026", "plain_what": "The FDA (the US drug regulator) will publish a formal safety alert or guidance document specifically warning doctors and patients about ibogaine's risk of heart damage\u2014QT prolongation and abnormal heart rhythms. This matters because it's the federal signal that ibogaine is officially unsafe, making it even harder for researchers to run trials or for companies to develop it." }, { "date": "2026-05-13", "title": "Ibogaine will not achieve federal NDA approval or Schedule I rescheduling before January 1, 2028.", "confidence": 88, "category": "regulation", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "ibogaine", "NDA", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine won't get federal approval or rescheduling by early 2028", "plain_what": "Ibogaine will remain federally illegal and unapproved as a medicine through the start of 2028. The FDA doesn't approve drugs without successful large-scale trials, which don't exist for ibogaine. The DEA won't reschedule it without FDA approval or a solid legal petition. The timeline is simply too short." }, { "date": "2026-05-13", "title": "A noribogaine or ibogaine-analogue biotech will announce a financing round above $30M (Series A or B) before end of Q1 2027, with communications explicitly referencing ibogaine cardiac liability as validating the safer-analogue development thesis.", "confidence": 38, "category": "market", "geography": "Global", "resolve_date": "2027-03-31", "tags": [ "ibogaine", "noribogaine", "biotech", "venture capital" ], "status": "pending", "priority": "high", "plain_title": "A safer ibogaine alternative will raise over $30M by spring 2027", "plain_what": "A biotech company will announce a major funding round\u2014Series A or B, more than $30 million\u2014for a drug that's designed to be a safer version of ibogaine. The company will publicly explain that they're building this alternative because of new research showing ibogaine damages the heart. This matters because it shows investors believe the problem is real and the safer-drug solution is worth betting on." }, { "date": "2026-05-14", "title": "Ibogaine neuroplasticity mechanism generates at least 5 major peer-reviewed mechanistic studies AND 2 dedicated research consortia by end of 2027, independent of clinical regulatory outcomes.", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2027-12-31", "tags": [ "ibogaine", "neuroplasticity", "basic-science" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine plasticity research spawns 5+ studies and 2 consortia by 2027", "plain_what": "Scientists discover ibogaine resets the brain's ability to form new connections like a juvenile brain does. This finding is so interesting that researchers and funders will support at least 5 major published studies and create 2 dedicated research groups to explore it \u2014 even if the FDA never approves ibogaine as medicine. This matters because it opens a whole new way to think about how ibogaine works, separate from whether it's actually safe to use as treatment." }, { "date": "2026-05-14", "title": "FDA issues a formal Drug Safety Communication on ibogaine cardiac risk (QT prolongation, ventricular arrhythmia) by Q4 2026.", "confidence": 44, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac-safety" ], "status": "pending", "priority": "high", "plain_title": "FDA issues formal cardiac safety warning on ibogaine by late 2026", "plain_what": "Three separate peer-reviewed studies have now identified that ibogaine can cause dangerous heart rhythm problems (QT prolongation and ventricular arrhythmia). When FDA (the US drug regulator) sees this kind of signal in published research, it typically issues a formal Drug Safety Communication warning doctors and the public. However, because ibogaine is currently Schedule I (completely illegal under federal law with no approved medical use), the FDA might decide it doesn't have to issue a formal warning \u2014 it's already illegal anyway. This matters because a formal warning carries legal weight and could influence state-level decisions about whether to allow ibogaine access." }, { "date": "2026-05-14", "title": "Ibogaine cardiac safety concerns produce a formal regulatory OR legislative response \u2014 FDA Safety Communication or congressional cardiac monitoring mandate \u2014 by end of 2026.", "confidence": 52, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac-safety", "legislation" ], "status": "pending", "priority": "high", "plain_title": "Federal regulators or Congress formally address ibogaine cardiac safety by 2026", "plain_what": "Ibogaine's cardiac risks are real and documented in peer-reviewed research. A formal response could come from either the FDA (a safety warning), or from Congress (a new law requiring cardiac monitoring for ibogaine access), or from another federal health agency. This broader framing makes formal action more likely than an FDA-specific warning, because if cardiac risks keep accumulating in the research, Congress \u2014 especially veterans' advocates who want ibogaine access for addiction treatment \u2014 might step in and say \"we need cardiac monitoring requirements.\" This matters because it signals the US government is taking the safety issue seriously, which influences what states do." }, { "date": "2026-05-14", "title": "State-level psychedelic access legislation remains the primary U.S. policy vector through end of 2027, with at least one state (California most likely) enacting a regulated access framework ahead of any federal scheduling or approval action.", "confidence": 72, "category": "legislation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "legislation", "California", "psychedelics", "state-policy" ], "status": "pending", "priority": "high", "plain_title": "States lead U.S. psychedelic policy ahead of federal action through 2027", "plain_what": "The federal government (the FDA and DEA) move slowly on approving new drugs \u2014 it takes 2+ years minimum, usually longer. Congress is gridlocked and doesn't move fast on drug policy. But individual states can act quickly. Oregon, Colorado, and especially California have bills moving through their legislatures right now to let people access psychedelics like psilocybin and MDMA under controlled, supervised conditions. It's very likely that at least one major state \u2014 probably California \u2014 will pass and implement a regulated psychedelic access framework before the FDA approves any psychedelic as medicine or before Congress changes federal drug law. This matters because it creates a real-world proof-of-concept that voters and other states will copy." }, { "date": "2026-05-15", "title": "FDA publishes formal guidance requiring cardiac monitoring infrastructure as prerequisite for ibogaine IND expansion or rescheduling petition before end of 2026", "confidence": 41, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac-safety" ], "status": "pending", "priority": "high", "plain_title": "FDA publishes cardiac monitoring rules for ibogaine trials by end of 2026", "plain_what": "The FDA (the US drug regulator) will likely publish formal written guidance saying that anyone running clinical trials with ibogaine must have hospital-grade heart monitoring equipment. This matters because ibogaine can cause dangerous heart rhythm problems, and the FDA needs to document the safety rules before more people can test it." }, { "date": "2026-05-15", "title": "Formal federal regulatory or legislative language codifying hospital-grade cardiac monitoring as a prerequisite for any ibogaine access pathway is published before 2026-08-13", "confidence": 7, "category": "regulation", "geography": "USA", "resolve_date": "2026-08-13", "tags": [ "ibogaine", "cardiac-safety", "legislation" ], "status": "pending", "priority": "high", "plain_title": "Federal ibogaine cardiac monitoring rules written into law by August 2026", "plain_what": "Congress or a federal agency will write ibogaine heart-monitoring requirements into actual legal language by mid-August 2026. This is much less likely than FDA guidance alone because Congress moves slowly and there's no emergency forcing the issue." }, { "date": "2026-05-15", "title": "The dissociation between extinction and relapse-prevention in the cocaine psilocybin RCT becomes a primary mechanistic research focus, generating an identifiable sub-literature of at least 10 peer-reviewed papers on consolidation vs. extinction within 24 months of publication", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2028-05-15", "tags": [ "psilocybin", "cocaine", "extinction", "consolidation", "mechanistic-research" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin-cocaine study sparks 10+ papers on brain mechanisms within 2 years", "plain_what": "A clinical trial combining psilocybin with cocaine addiction treatment will show an unusual result: people's brains learn to stop craving cocaine, but they also don't relapse the way brain science predicts. This contradiction will be so interesting that scientists will publish at least 10 peer-reviewed papers in the next two years trying to explain which parts of the brain are really responsible." }, { "date": "2026-05-15", "title": "Ibogaine remains Schedule I through 2028 with no rescheduling petition advancing past initial DEA review", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2028-12-31", "tags": [ "ibogaine", "DEA", "Schedule I", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine stays illegal Schedule I drug through 2028", "plain_what": "Ibogaine will remain a Schedule I controlled substance (the strictest category, meaning no approved medical use) through 2028 because the US government almost never moves drugs down from Schedule I. Even if someone files a formal petition asking the DEA (the US drug enforcement agency) to reconsider, the DEA will likely reject it or sit on it without action." }, { "date": "2026-05-15", "title": "At least $50M in new NIH and DARPA grant awards targeting ibogaine analog development and neuroplasticity mechanism characterization is announced within 18 months of 2026-05-15", "confidence": 38, "category": "research", "geography": "USA", "resolve_date": "2027-11-15", "tags": [ "ibogaine", "NIH", "DARPA", "neuroplasticity", "funding" ], "status": "pending", "priority": "high", "plain_title": "US government funds $50M+ ibogaine research and plasticity studies by late 2027", "plain_what": "The US government\u2014through the NIH (National Institutes of Health) or DARPA (the Defense Department's research agency)\u2014will announce at least $50 million in new research grants for ibogaine and brain plasticity studies by late 2027. This matters because government funding signals that ibogaine is moving from fringe to mainstream science, and the money enables labs to do expensive mechanistic research." }, { "date": "2026-05-16", "title": "FDA will issue formal ibogaine cardiac safety guidance requiring mandatory cardiac screening protocols before any IND expansion, delaying veteran-focused trials by 12-18 months", "confidence": 62, "category": "regulatory", "geography": "USA", "resolve_date": "2027-03-01", "tags": [ "ibogaine", "FDA", "veteran" ], "status": "pending", "priority": "high", "plain_title": "FDA demands heart screening before ibogaine trials expand", "plain_what": "The FDA (US drug regulator) will require companies to do cardiac screening tests before expanding ibogaine studies, because recent research shows ibogaine can affect heart rhythm. This slows down trials \u2014 especially ones for veterans \u2014 by over a year." }, { "date": "2026-05-16", "title": "At least three non-hallucinogenic structural ibogaine analogues will enter preclinical development within 36 months, driven by neuroplasticity mechanism findings", "confidence": 61, "category": "research", "geography": "Global", "resolve_date": "2029-05-01", "tags": [ "ibogaine", "neuroplasticity", "drug-development" ], "status": "pending", "priority": "high", "plain_title": "Three non-psychedelic ibogaine drugs will start lab testing", "plain_what": "Researchers will start developing versions of ibogaine that don't make you hallucinate but keep the healing effects by targeting brain plasticity. Companies will invest in these because they're easier to regulate and market." }, { "date": "2026-05-16", "title": "At least two sponsors will submit accelerated approval pathway applications to FDA for psilocybin-based therapies by November 2027", "confidence": 38, "category": "regulatory", "geography": "USA", "resolve_date": "2027-11-01", "tags": [ "psilocybin", "FDA", "clinical-trials" ], "status": "pending", "priority": "high", "plain_title": "Two companies will ask FDA for fast-track psilocybin approval", "plain_what": "Psilocybin therapy companies have good clinical trial data on depression and suicidal thoughts. Two of them will ask the FDA (US drug regulator) for an expedited approval process called 'accelerated approval,' which is faster than normal. But the FDA may say no because of how hard it is to run psilocybin trials fairly." }, { "date": "2026-05-16", "title": "A formal congressional study commission on psychedelic medicine will be established via NDAA or standalone legislation before end of 2026, but no scheduling or prescribing legislation will pass before 2028", "confidence": 58, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "legislation", "NDAA", "psychedelics" ], "status": "pending", "priority": "high", "plain_title": "Congress forms psychedelic study group before 2027, no laws until 2028", "plain_what": "Congress will create an official commission to study psychedelic medicine\u2014likely tucked into the National Defense Authorization Act (NDAA), which funds the military\u2014because both parties like supporting veterans. But nobody will actually change drug laws or let doctors prescribe psychedelics before 2028." }, { "date": "2026-05-17", "title": "At least 5 NIH-funded mechanistic follow-up studies on ibogaine's neural plasticity mechanism will be awarded within 2 years, with at least one study explicitly targeting non-hallucinogenic analogue development.", "confidence": 55, "category": "research", "geography": "USA", "resolve_date": "2028-05-17", "tags": [ "ibogaine", "NIH", "plasticity" ], "status": "pending", "priority": "high", "plain_title": "NIH funds 5+ ibogaine brain studies within 2 years, including non-hallucinogenic versions", "plain_what": "The US government's National Institutes of Health (NIH) will award at least 5 research grants studying how ibogaine changes the brain and how scientists might create similar drugs without the psychedelic effects. This matters because it signals that federal science institutions see real promise in ibogaine as a medicine, not just a drug of abuse." }, { "date": "2026-05-17", "title": "The cocaine-psilocybin 'extinction without relapse prevention' finding will be cited by name in at least 3 pieces of formal anti-psychedelic congressional testimony or submitted written statements within 12 months of publication.", "confidence": 28, "category": "legislation", "geography": "USA", "resolve_date": "2027-05-17", "tags": [ "psilocybin", "cocaine", "congress" ], "status": "pending", "priority": "medium", "plain_title": "Anti-drug politicians cite psilocybin-cocaine study in congressional testimony within 12 months", "plain_what": "A recent study found that psilocybin might help people with cocaine addiction by erasing addiction memories without preventing relapse\u2014a genuine finding that critics of psychedelics could use in Congress. The prediction is that at least 3 formal pieces of congressional testimony or written statements will specifically name and cite this study to argue against psychedelic legalization within one year of publication." }, { "date": "2026-05-17", "title": "FDA will issue formal written cardiac safety guidance or a mandatory cardiac screening requirement specifically for ibogaine INDs before June 2027, materially delaying at least one active veteran access program.", "confidence": 52, "category": "regulatory", "geography": "USA", "resolve_date": "2027-06-01", "tags": [ "ibogaine", "FDA", "cardiac", "veteran" ], "status": "pending", "priority": "high", "plain_title": "FDA requires heart screening for ibogaine before therapeutic programs start", "plain_what": "Ibogaine can affect the heart's electrical rhythm, which worries regulators. The FDA may issue formal written safety requirements that anyone using ibogaine in a clinical program must have their heart tested first. This would slow down at least one current ibogaine program by at least 18 months because they'd have to add new testing requirements and get FDA approval for the changes." }, { "date": "2026-05-17", "title": "Mandatory federal cardiac safety protocols for ibogaine will be required before any regulated U.S. therapeutic access program launches, causing delays of at least 18 months beyond currently projected timelines.", "confidence": 18, "category": "regulatory", "geography": "USA", "resolve_date": "2026-08-15", "tags": [ "ibogaine", "cardiac", "FDA" ], "status": "pending", "priority": "high", "plain_title": "Federal ibogaine cardiac safety rules delay therapeutic access by 18+ months", "plain_what": "Before the FDA allows any legal therapeutic ibogaine program in the US, federal regulators may require mandatory cardiac safety protocols (heart tests and screening). This prediction says such rules will exist and will push back timelines for at least one active program trying to help veterans get access to ibogaine by at least 18 months from current projections." }, { "date": "2026-05-17", "title": "No psychedelic substance (psilocybin, MDMA, ibogaine, ketamine analogues, or LSD) will be federally rescheduled from Schedule I in the United States before January 1, 2028.", "confidence": 82, "category": "regulatory", "geography": "USA", "resolve_date": "2028-01-01", "tags": [ "rescheduling", "DEA", "FDA", "psilocybin", "MDMA", "ibogaine" ], "status": "pending", "priority": "high", "plain_title": "No psychedelic drug becomes legal medicine in US before 2028", "plain_what": "Psilocybin, MDMA, ibogaine, ketamine-like drugs, or LSD will not be moved from Schedule I (the DEA's most restrictive category for illegal drugs with no medical use) to a lower schedule by the US government before January 1, 2028. This matters because as long as they stay Schedule I, doctors cannot prescribe them legally, even in clinical trials, even if they work." }, { "date": "2026-05-17", "title": "Psychedelic biotech sector equities (as measured by a basket of publicly traded psychedelic companies) will show negative or flat returns through Q4 2026 absent a concrete FDA approval or positive advisory committee vote for a psychedelic compound.", "confidence": 68, "category": "market", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "biotech", "equities", "FDA", "psychedelics" ], "status": "pending", "priority": "high", "plain_title": "Psychedelic company stocks stay flat or lose money through 2026", "plain_what": "Publicly traded companies that develop psychedelic medicines will have negative or flat stock returns through the end of 2026 unless the FDA approves a psychedelic medicine or an FDA advisory committee votes to recommend approval. This matters because it signals whether investors believe these companies will succeed or whether the FDA rejection of MDMA has killed momentum." }, { "date": "2026-05-18", "title": "FDA will issue formal ibogaine cardiac safety guidance requiring mandatory cardiac screening protocols before any IND approval proceeds, by Q1 2027.", "confidence": 82, "category": "regulation", "geography": "USA", "resolve_date": "2027-03-31", "tags": [ "ibogaine", "FDA" ], "status": "pending", "priority": "high", "plain_title": "FDA will require heart screening before approving ibogaine studies", "plain_what": "The FDA (the US drug regulator) will write formal rules saying anyone testing ibogaine must get heart tests first, because recent research shows ibogaine can cause dangerous heart rhythms. This matters because it slows down ibogaine research but protects people from cardiac injury." }, { "date": "2026-05-18", "title": "Psilocybin cocaine RCT extinction-without-relapse-prevention finding will generate 3+ follow-up mechanistic studies within 18 months investigating default mode network suppression during extinction learning.", "confidence": 79, "category": "research", "geography": "Global", "resolve_date": "2027-11-18", "tags": [ "psilocybin" ], "status": "pending", "priority": "high", "plain_title": "Researchers will study why psilocybin blocks cocaine relapse so effectively", "plain_what": "Scientists just found that psilocybin (the active compound in magic mushrooms) helps people learn to stop craving cocaine without needing the usual relapse prevention therapy. Neuroscientists will now run 3+ new studies to figure out exactly which brain circuits make this work, because it's a genuinely novel mechanism that could unlock new addiction treatments." }, { "date": "2026-05-18", "title": "Senate Veterans Affairs Committee will hold ibogaine-specific hearings with Stanford researchers testifying before September 2026.", "confidence": 78, "category": "legislation", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "ibogaine", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Senate will hold ibogaine hearings with Stanford researchers by September 2026", "plain_what": "The US Senate Committee that oversees veterans healthcare will hold public hearings specifically about ibogaine for addiction treatment, with Stanford researchers presenting evidence. This happens because veterans are advocating for ibogaine access and senators need to understand both the promise and the recent cardiac safety concerns before they act." }, { "date": "2026-05-18", "title": "A major investigative piece linking ibogaine cardiac deaths specifically to veteran treatment programs will publish in a top-tier outlet before August 2026.", "confidence": 76, "category": "culture", "geography": "USA", "resolve_date": "2026-08-01", "tags": [ "ibogaine", "DEA", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Major news outlet will expose ibogaine cardiac deaths in veteran programs", "plain_what": "A major investigative journalist will publish a detailed story in a top-tier news outlet linking deaths from ibogaine-related heart problems specifically to veteran treatment programs. This story will combine new research on QT prolongation (heart rhythm danger) with opioid interaction risks, creating enough concrete evidence that editors will green-light the investigation." }, { "date": "2026-05-18", "title": "CMPS will outperform MMED by at least 15% on a 6-month basis as psilocybin depression RCT data is absorbed by institutional allocators.", "confidence": 74, "category": "market", "geography": "Global", "resolve_date": "2026-11-18", "tags": [ "psilocybin", "depression" ], "status": "pending", "priority": "medium", "plain_title": "Compass stock outperforms MindMed on psilocybin depression data", "plain_what": "Compass Pathways' stock will perform better than MindMed's stock (by at least 15% over 6 months) because Compass just published strong depression trial results, while MindMed has weaker clinical data. Institutional money managers follow randomized controlled trial results, not hype\u2014and Compass has cleaner evidence in a validated indication (depression)." }, { "date": "2026-05-18", "title": "Psilocybin will receive Breakthrough Therapy Designation for cocaine use disorder within 12 months based on today's RCT data.", "confidence": 71, "category": "regulation", "geography": "Global", "resolve_date": "2027-05-18", "tags": [ "psilocybin" ], "status": "pending", "priority": "medium", "plain_title": "", "plain_what": "" }, { "date": "2026-05-18", "title": "California will enact a regulated psilocybin therapy framework by end of 2027, becoming the largest state-sanctioned psychedelic therapy market.", "confidence": 70, "category": "legislation", "geography": "Global", "resolve_date": "2027-12-31", "tags": [ "psilocybin", "California", "market" ], "status": "pending", "priority": "medium", "plain_title": "", "plain_what": "" }, { "date": "2026-05-19", "title": "The psilocybin cocaine RCT will be significantly misrepresented in at least three major mainstream media outlets within 72 hours of publication, and a researcher-led public correction effort will itself generate coverage framing psychedelic science as prone to hype cycles", "confidence": 62, "category": "culture", "geography": "Global", "resolve_date": "2026-05-22", "tags": [ "psilocybin", "media", "cocaine", "RCT", "science-communication" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin-cocaine study gets mangled in 72 hours, then correction itself becomes a credibility scandal", "plain_what": "When researchers publish a surprising finding about psilocybin and cocaine addiction, mainstream news outlets will oversimplify or misrepresent the actual results within three days. When scientists try to publicly correct these errors, journalists will frame the whole situation as evidence that psychedelic science hypes itself up\u2014turning the correction effort into another credibility problem instead of fixing the original one." }, { "date": "2026-05-19", "title": "Ibogaine will remain Schedule I through December 31, 2029, with DEA's 8-factor analysis citing cardiac liability as sufficient procedural basis to deny rescheduling despite active IND filings and veteran advocacy pressure", "confidence": 71, "category": "regulation", "geography": "USA", "resolve_date": "2029-12-31", "tags": [ "ibogaine", "DEA", "Schedule I", "cardiac", "veteran", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine stays illegal through 2029 because of heart risks, despite veteran pressure", "plain_what": "Ibogaine\u2014a West African plant used by some to treat addiction\u2014will remain a Schedule I controlled substance (meaning illegal with no accepted medical use) through the end of 2029. The DEA (the US drug enforcement agency) will cite documented cardiac (heart) dangers as their reason to reject rescheduling, even though veterans and activists push hard for legal access and companies are already running FDA (US drug regulator) approved clinical trials." }, { "date": "2026-05-19", "title": "CMPS (Compass Pathways) will not recover above $12.50 by August 19, 2026, confirming that publication volume is not an investable catalyst and only binary FDA events or M&A signals move institutional psychedelic capital", "confidence": 67, "category": "market", "geography": "USA", "resolve_date": "2026-08-19", "tags": [ "CMPS", "Compass Pathways", "psychedelic", "biotech", "FDA", "institutional-capital" ], "status": "pending", "priority": "high", "plain_title": "Compass Pathways stock won't bounce back above $12.50 by August 2026", "plain_what": "Compass Pathways (CMPS)\u2014a company developing psilocybin therapy\u2014will not see its stock price climb back above $12.50 by mid-August 2026. This matters because it shows that publishing research papers and positive clinical results alone don't move stock prices anymore. Only big announcements (FDA approval meetings, or one company buying another) actually make institutional investors (the big money players) move." }, { "date": "2026-05-20", "title": "Psilocybin will remain Schedule I through end of 2027, as no NDA has been filed and DEA rescheduling requires completion of a formal administrative process that FDA approval would trigger but publication volume cannot accelerate.", "confidence": 88, "category": "regulatory", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "psilocybin", "DEA", "Schedule I", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin stays illegal until at least end of 2027", "plain_what": "Psilocybin will almost certainly remain a Schedule I drug (illegal with no accepted medical use) through 2027 because no company has yet filed an NDA (the FDA application required to approve a new drug). Even after an NDA is approved, the DEA (the federal agency that controls drug legality) needs 12-24+ months to formally change psilocybin's legal status. Since the clock hasn't even started, rescheduling by 2028 is unlikely." }, { "date": "2026-05-20", "title": "At least one major mainstream US news outlet will publish a headline characterizing the cocaine use disorder psilocybin RCT results as evidence that 'psychedelics cure addiction' within 30 days of publication, followed by a correction cycle that complicates congressional messaging.", "confidence": 78, "category": "culture", "geography": "USA", "resolve_date": "2026-06-20", "tags": [ "psilocybin", "addiction", "media", "cocaine use disorder" ], "status": "pending", "priority": "high", "plain_title": "Major news will hype psilocybin addiction cure, then quietly correct", "plain_what": "When researchers announce that psilocybin helped people quit cocaine, major news outlets will publish headlines saying psychedelics 'cure addiction'\u2014even though the actual finding is much narrower (psilocybin reduced cravings in one study). Within 2-4 weeks, scientists and careful reporters will publish corrections and pushback. This cycle confuses the public and makes Congress skeptical of psychedelic funding." }, { "date": "2026-05-20", "title": "A psilocybin NDA for treatment-resistant MDD will be filed with the FDA by COMPASS Pathways or a direct competitor by November 2027, citing recent RCT data as supportive evidence alongside existing Phase 3 results.", "confidence": 62, "category": "regulatory", "geography": "USA", "resolve_date": "2027-11-30", "tags": [ "psilocybin", "COMPASS", "NDA", "treatment-resistant MDD", "Phase 3" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin NDA filed for depression treatment by late 2027", "plain_what": "COMPASS Pathways or a competitor will likely submit an NDA (formal approval application) to the FDA by November 2027 for psilocybin as a treatment for severe depression that doesn't respond to other drugs. They have completed Phase 3 trials (the final human testing stage) and have publicly said they're preparing the application. This doesn't mean psilocybin will be approved or legal yet\u2014just that the formal FDA review process will begin." }, { "date": "2026-05-20", "title": "The ibogaine juvenile plasticity finding will generate at least 3 NIH R01 grant awards (not merely applications) specifically targeting critical period plasticity mechanisms within 18 months of May 2026.", "confidence": 38, "category": "research", "geography": "USA", "resolve_date": "2027-11-20", "tags": [ "ibogaine", "NIH", "critical period plasticity", "R01", "neuroscience funding" ], "status": "pending", "priority": "high", "plain_title": "Ibogaine brain plasticity finding sparks three NIH grants", "plain_what": "A recent discovery that ibogaine (a psychedelic) can reopen brain plasticity windows in adults is so important that the NIH (US medical research agency) will likely fund at least three R01 grants (major research awards) specifically to study how this works. This is aggressive because NIH typically funds only 1 in 5 grant proposals, and the finding needs time to get recognized and peer-reviewed. Within 18 months of May 2026 (by late 2027) is the deadline." }, { "date": "2026-05-21", "title": "FDA will formally require prospective cardiac monitoring REMS as a non-negotiable precondition for any ibogaine IND approval in veteran-access programs by Q1 2027", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2027-03-01", "tags": [ "ibogaine", "FDA", "REMS", "veteran", "cardiac" ], "status": "pending", "priority": "high", "plain_title": "FDA will require heart monitoring for ibogaine veteran programs by early 2027", "plain_what": "The FDA (the US drug regulator) will make cardiac monitoring a non-negotiable requirement before approving ibogaine for veterans. Recent safety studies show ibogaine can cause heart problems, so the FDA will use formal risk management agreements to ensure hospitals monitor patients' hearts. This matters because it affects whether veterans can legally access ibogaine for PTSD and addiction through approved channels." }, { "date": "2026-05-21", "title": "The number of identifiable US-based or Mexico/Caribbean-based retreats explicitly marketing to US veterans for ibogaine treatment will be at least 40% higher than current baseline by 2027-05-21", "confidence": 63, "category": "market", "geography": "USA", "resolve_date": "2027-05-21", "tags": [ "ibogaine", "veteran", "gray-market", "retreats", "demand" ], "status": "pending", "priority": "high", "plain_title": "US ibogaine retreats marketing to veterans will grow 40% by mid-2027", "plain_what": "The number of treatment retreats in the US and nearby countries (Mexico, Caribbean islands) that explicitly market ibogaine to US veterans will jump by at least 40%. Veterans hear about positive results from other vets through social media and informal networks, and many don't want to wait for the slow FDA approval process. This matters because unregulated retreats have no safety oversight." }, { "date": "2026-05-21", "title": "A documented fatality at a US-based or US-citizen-attended gray-market ibogaine retreat will receive national mainstream media coverage and prompt at least one congressional hearing within 12 months", "confidence": 61, "category": "regulation", "geography": "USA", "resolve_date": "2026-05-21", "tags": [ "ibogaine", "gray-market", "fatality", "congress", "veteran" ], "status": "pending", "priority": "high", "plain_title": "A death at an unregulated ibogaine retreat will trigger congressional investigation", "plain_what": "Someone will die at an ibogaine retreat that operates without FDA oversight, and that death will make national news and spark a congressional hearing. Ibogaine can cause serious heart problems, and many retreats don't have cardiac monitoring. Veterans seeking treatment have additional heart risks from injuries and medication use. When a high-profile death occurs, Congress will demand answers about why this treatment isn't regulated." }, { "date": "2026-05-21", "title": "At least one major pharmaceutical company (top-20 by revenue) will announce a psilocybin licensing deal or acquisition of COMPASS Pathways or ATAI Life Sciences by 2027-02-21", "confidence": 52, "category": "market", "geography": "USA", "resolve_date": "2027-02-21", "tags": [ "psilocybin", "pharma", "COMPASS", "ATAI", "acquisition" ], "status": "pending", "priority": "medium", "plain_title": "A major pharmaceutical company will acquire a psilocybin psychedelic firm by early 2027", "plain_what": "One of the world's twenty largest drug companies will buy or license psilocybin (the active compound in magic mushrooms) from COMPASS Pathways or ATAI Life Sciences, the two main public companies developing it. These companies have successful clinical trial results that prove psilocybin works for depression and other conditions. Big pharma sees that their old product lines are running out of patent protection, so they're buying new breakthrough treatments. This matters because it means psilocybin could become a mainstream medicine." }, { "date": "2026-05-21", "title": "At least three NIH R01 or equivalent grant applications explicitly targeting ibogaine's cortical plasticity mechanism in non-addiction CNS indications (amblyopia, stroke, TBI) will be funded within 18 months", "confidence": 48, "category": "research", "geography": "USA", "resolve_date": "2026-11-21", "tags": [ "ibogaine", "NIH", "plasticity", "TBI", "stroke", "amblyopia" ], "status": "pending", "priority": "medium", "plain_title": "NIH will fund at least three ibogaine plasticity research grants within 18 months", "plain_what": "The National Institutes of Health (NIH, the US government's medical research agency) will award at least three major research grants focused on how ibogaine helps the brain rebuild neural connections in conditions like amblyopia (lazy eye), stroke, and traumatic brain injury. These studies are scientifically straightforward and don't involve addiction treatment, which makes them less politically controversial. This matters because government funding legitimizes the research and could open new medical uses." }, { "date": "2026-05-22", "title": "FDA will issue formal guidance requiring mandatory cardiac monitoring protocols for ibogaine INDs before end of 2026", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "FDA", "cardiac", "IND" ], "status": "pending", "priority": "high", "plain_title": "FDA requires heart monitoring for ibogaine clinical trials by end of 2026", "plain_what": "The FDA (the US drug regulator) will publish formal written guidance saying that any scientist testing ibogaine must monitor patients' hearts for dangerous rhythm problems. This matters because ibogaine can affect heart electrical activity, and the FDA has the data to back up this requirement\u2014it just needs to publish the rule." }, { "date": "2026-05-22", "title": "Veterans will be the named beneficiary population in the majority of psychedelic access bills introduced in US state legislatures in 2026, with ibogaine bills outnumbering psilocybin or MDMA bills", "confidence": 68, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "ibogaine", "psilocybin", "MDMA", "legislation", "veteran" ], "status": "pending", "priority": "high", "plain_title": "Most new state psychedelic bills in 2026 target veterans with ibogaine", "plain_what": "When state lawmakers introduce new bills about psychedelic access in 2026, most will specifically name veterans with PTSD or traumatic brain injury as the target group\u2014and more will mention ibogaine than psilocybin or MDMA. This matters because it shows where political energy is moving: away from broad public access and toward a narrow, bipartisan coalition around veteran treatment." }, { "date": "2026-05-22", "title": "DEA will initiate at least two publicly announced enforcement actions against unlicensed psychedelic clinic operators before end of 2026", "confidence": 65, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "ketamine", "DEA", "enforcement", "Schedule I" ], "status": "pending", "priority": "high", "plain_title": "DEA will publicly charge at least two unlicensed psychedelic clinics by end of 2026", "plain_what": "The DEA (US drug enforcement agency) will announce at least two enforcement actions against clinics operating without proper registration or licenses to give psychedelic drugs. This matters because as states create new psilocybin and ketamine clinics, many operators skip DEA paperwork, and the agency needs to show it's still relevant and enforcing rules." }, { "date": "2026-05-22", "title": "No new psychedelic compound will receive FDA Breakthrough Therapy Designation in 2026", "confidence": 61, "category": "regulation", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "FDA", "breakthrough therapy", "psilocybin", "MDMA", "ibogaine" ], "status": "pending", "priority": "medium", "plain_title": "No new psychedelic will get FDA fast-track approval status in 2026", "plain_what": "No psychedelic drug will earn Breakthrough Therapy Designation (a special FDA fast-track label) in 2026. This matters because it shows that the FDA's skepticism is real and growing\u2014the agency is now scrutinizing whether trial results are actually solid or just reflect placebo effects and experimenter bias." }, { "date": "2026-05-22", "title": "At least two US states will enact Right-to-Try or expanded access legislation explicitly naming ibogaine for veteran PTSD or TBI treatment before 2027-07-01", "confidence": 52, "category": "legislation", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "ibogaine", "right-to-try", "veteran", "state legislation" ], "status": "pending", "priority": "high", "plain_title": "Two states will pass ibogaine access laws for veterans before July 2027", "plain_what": "At least two US states will pass laws allowing veterans with PTSD or traumatic brain injury to access ibogaine outside normal FDA clinical trial rules (called right-to-try or expanded access). This matters because state legislatures can move faster than federal agencies, and the veteran community has real political power\u2014both conservative and liberal lawmakers support veteran access to new treatments." }, { "date": "2026-05-23", "title": "Mainstream media will materially misrepresent at least one psilocybin RCT finding published in May 2026 within 60 days, with a named researcher publicly issuing a correction request by August 21, 2026.", "confidence": 78, "category": "culture", "geography": "Global", "resolve_date": "2026-07-22", "tags": [ "psilocybin", "media", "research-communication" ], "status": "pending", "priority": "high", "plain_title": "News outlet will badly distort a psilocybin study finding by August 2026", "plain_what": "A major news organization will publish a misleading headline or story about a psilocybin research study released in May 2026. A scientist involved in the research will publicly ask for a correction. This happens because journalists often oversimplify complicated study results to meet deadlines, and the science here involves tricky distinctions that are easy to flatten into false claims." }, { "date": "2026-05-23", "title": "DEA will submit formal written opposition to any NDAA ibogaine veteran access amendment before the Senate Armed Services Committee markup, citing cardiac safety data and Schedule I diversion risk.", "confidence": 76, "category": "legislation", "geography": "USA", "resolve_date": "2026-09-01", "tags": [ "ibogaine", "DEA", "veteran", "NDAA" ], "status": "pending", "priority": "high", "plain_title": "DEA will formally oppose letting military veterans access ibogaine", "plain_what": "Congress may try to let military veterans use ibogaine (an illegal plant medicine) to treat addiction or PTSD through a special amendment. The DEA (the US drug enforcement agency) will file official written testimony against this, citing two concerns: ibogaine can cause dangerous heart rhythm changes, and people might illegally sell it. The DEA does this routinely when Congress tries to bypass normal drug approval channels." }, { "date": "2026-05-23", "title": "Ibogaine cardiac safety will remain the primary stated regulatory bottleneck blocking IND expansion in the US through June 30, 2027, with no FDA formal guidance issued permitting expanded ibogaine trials without mandatory cardiac monitoring protocols.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2027-06-30", "tags": [ "ibogaine", "FDA", "cardiac-safety", "regulatory" ], "status": "pending", "priority": "high", "plain_title": "FDA will keep requiring heart monitoring for ibogaine trials through mid-2027", "plain_what": "Ibogaine is a powerful plant medicine that can affect heart rhythm (a condition called QTc prolongation that can cause sudden cardiac death). The FDA (the US drug regulator) requires anyone running an ibogaine clinical trial to monitor patients' hearts carefully. Until June 30, 2027, the FDA will not issue new written guidance that lets researchers skip or reduce heart monitoring, even though heart monitoring makes trials expensive and hard to run at scale." }, { "date": "2026-05-23", "title": "The ibogaine visual cortex plasticity finding will be cited by at least 5 peer-reviewed mechanistic studies at independent institutions by May 23, 2027, expanding ibogaine's scientific framing beyond addiction.", "confidence": 62, "category": "research", "geography": "Global", "resolve_date": "2027-05-23", "tags": [ "ibogaine", "neuroplasticity", "research" ], "status": "pending", "priority": "medium", "plain_title": "Scientists will cite ibogaine brain plasticity finding in five new studies by May 2027", "plain_what": "A recent study found that ibogaine can make the adult brain behave like a young brain (increasing neuroplasticity, or the brain's ability to rewire itself). Over the next 18 months, at least five independent research groups at different institutions will publish their own studies citing this finding. They'll explore whether this brain-rewiring effect could help with other conditions like lazy eye (amblyopia), PTSD, or stroke recovery \u2014 not just addiction." }, { "date": "2026-05-23", "title": "A major mainstream outlet (top-50 US or UK publication by traffic) will publish a feature conflating psilocybin cocaine use disorder trial findings with recreational microdosing trends by July 7, 2026, generating at least one named researcher publicly objecting within 14 days of publication.", "confidence": 48, "category": "culture", "geography": "Global", "resolve_date": "2026-07-07", "tags": [ "psilocybin", "microdosing", "media" ], "status": "pending", "priority": "medium", "plain_title": "Major news outlet will confuse psilocybin addiction research with recreational microdosing by July 2026", "plain_what": "A major news organization will publish a feature story that mixes up two completely different things: (1) a clinical trial using psilocybin to treat cocaine addiction through a specific mechanism called extinction learning, and (2) people taking tiny doses of psilocybin recreationally. The outlet will imply they work the same way because both involve psilocybin and 'brain change.' A named researcher will publicly object within two weeks." }, { "date": "2026-05-24", "title": "Psilocybin remains federally Schedule I in the USA through December 31, 2028.", "confidence": 85, "category": "regulation", "geography": "USA", "resolve_date": "2028-12-31", "tags": [ "psilocybin", "Schedule I", "DEA", "rescheduling" ], "status": "pending", "priority": "high", "plain_title": "Psilocybin stays illegal at federal level through 2028", "plain_what": "The U.S. federal government will keep psilocybin classified as Schedule I (most dangerous, no medical use) through the end of 2028. This matters because even if your state allows it, federal law still applies \u2014 you can still face federal charges, and banks won't touch businesses selling it. Moving psilocybin to a lower schedule requires the FDA (the U.S. drug regulator) to approve it as medicine first, then the DEA (the federal drug enforcement agency) to officially change its category, a process that takes years even after FDA approval." }, { "date": "2026-05-24", "title": "No U.S. state beyond Oregon and Colorado enacts a legal therapeutic psilocybin access framework (not just decriminalization) signed into law before January 1, 2028.", "confidence": 72, "category": "regulation", "geography": "USA", "resolve_date": "2027-12-31", "tags": [ "psilocybin", "state law", "therapeutic access", "legalization" ], "status": "pending", "priority": "high", "plain_title": "Only Oregon and Colorado approve legal psilocybin therapy by 2028", "plain_what": "No other U.S. state will pass a law creating a legal framework for people to access psilocybin therapy (not just decriminalization, but an actual licensed system) before January 2028. This matters because it determines whether your state offers any legal route to the treatment. Oregon and Colorado are moving slowly and hitting real problems setting up their systems, which is cooling other states' enthusiasm. Most states are in a 'let's wait and see how this goes' mode rather than drafting their own laws." }, { "date": "2026-05-24", "title": "At least three peer-reviewed papers on psychedelic neuroplasticity mechanisms are published in Nature-family or Cell-family journals in calendar year 2026.", "confidence": 65, "category": "research", "geography": "Global", "resolve_date": "2026-12-31", "tags": [ "neuroplasticity", "psilocybin", "peer-reviewed", "Nature", "Cell", "basic science" ], "status": "pending", "priority": "medium", "plain_title": "Three major science journals publish psychedelic brain research in 2026", "plain_what": "Three or more papers explaining exactly how psychedelics change the brain will appear in the world's most prestigious science journals (Nature Neuroscience, Nature Medicine, Cell, or Neuron) in calendar year 2026. This matters because these papers establish the biological mechanism \u2014 the proof that these drugs actually rewire brain circuits in real, measurable ways. This evidence builds the case for medical use and attracts serious research funding." }, { "date": "2026-05-24", "title": "At least one Phase 3 psychedelic trial (psilocybin for MDD or a supplemental MDMA-PTSD study) reports a statistically significant primary endpoint result by December 31, 2026.", "confidence": 62, "category": "research", "geography": "USA", "resolve_date": "2026-12-31", "tags": [ "psilocybin", "MDMA", "Phase 3", "clinical trial", "MDD", "PTSD" ], "status": "pending", "priority": "high", "plain_title": "A Phase 3 psychedelic trial hits its main goal by late 2026", "plain_what": "At least one large final-stage clinical trial testing psilocybin for depression or MDMA (a related psychedelic) for PTSD will report that the drug actually works as hoped by the end of 2026. This matters because Phase 3 trials are the final hurdle before the FDA decides whether to approve a drug for doctors to prescribe. If one succeeds, it proves the drug works, brings approval closer, and validates the whole industry's approach." }, { "date": "2026-05-24", "title": "Psychedelic therapy research provisions are included in the FY2027 NDAA or a VA appropriations bill passed by December 15, 2026.", "confidence": 58, "category": "legislation", "geography": "USA", "resolve_date": "2026-12-15", "tags": [ "legislation", "veteran", "NDAA", "VA", "psychedelic research" ], "status": "pending", "priority": "medium", "plain_title": "Congress funds psychedelic research for veterans by late 2026", "plain_what": "The U.S. Congress will approve money to fund psychedelic research for veterans \u2014 likely by tucking it into a must-pass military spending bill (the National Defense Authorization Act, or NDAA) or a Veterans Administration budget bill by mid-December 2026. This matters because Congress has already done this twice (in 2022 and 2023), showing veteran psychedelic research has real legislative support. Money means trials start, evidence accumulates, and veterans get earlier access to potential treatments." }, { "date": "2026-05-25", "title": "FDA issues a Complete Response Letter for MDMA-assisted therapy, citing inadequate blinding controls and therapist fidelity data, requiring at least one additional trial before resubmission.", "confidence": 74, "category": "regulatory", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "MDMA", "FDA", "MDMA-AT", "CRL" ], "status": "pending", "priority": "high", "plain_title": "FDA rejects MDMA therapy, demands another trial on blinding", "plain_what": "The FDA (the US drug regulator) will send back Lykos's MDMA-assisted therapy application with a Complete Response Letter \u2014 a formal rejection. The FDA will specifically cite two problems: the study wasn't properly blinded (meaning patients and therapists might have known who got real MDMA vs. placebo), and they don't have enough data on whether therapists followed the protocol consistently. This matters because it delays MDMA therapy by 3-5 years and signals the FDA is tightening its standards after the messy Lykos approval fight last year." }, { "date": "2026-05-25", "title": "Stanford's DOD-funded ibogaine veteran trial will publicly release preliminary outcomes data by Q3 2026, directly cited in at least one congressional hearing or formal Senate briefing.", "confidence": 72, "category": "research", "geography": "USA", "resolve_date": "2026-09-30", "tags": [ "ibogaine", "veteran", "Stanford", "Congress" ], "status": "pending", "priority": "high", "plain_title": "Stanford's ibogaine study releases veteran outcomes by mid-2026", "plain_what": "Stanford University, funded by the US Department of Defense (DOD), is running a trial of ibogaine for military veterans with PTSD and substance use disorder. By Q3 2026 (summer/fall), they will publish early results showing whether ibogaine actually helps these veterans. This matters because veterans' groups and their congressional allies are waiting for this data to push for policy change \u2014 ibogaine is currently illegal in the US." }, { "date": "2026-05-25", "title": "A named veteran will deliver live or recorded congressional testimony specifically about personal ibogaine treatment outcomes before September 2026, constituting the highest-profile psychedelic policy moment of the year.", "confidence": 68, "category": "culture", "geography": "USA", "resolve_date": "2026-08-31", "tags": [ "ibogaine", "veteran", "Congress", "testimony" ], "status": "pending", "priority": "high", "plain_title": "A veteran testifies to Congress about their ibogaine treatment", "plain_what": "A named veteran will go to Capitol Hill \u2014 either in person or via recorded video testimony \u2014 and tell members of Congress that ibogaine treated their PTSD, substance use, or both. Congress will hold a formal hearing or briefing. This will be the biggest psychedelic moment in politics that year because veteran testimony is extremely powerful in Congress, and it will come right after Stanford releases their data (see above), giving the story scientific weight." }, { "date": "2026-05-25", "title": "A peer-reviewed meta-analysis formally quantifying blinding failure rates across MDMA-AT randomized controlled trials will be published in a journal with impact factor >5 by Q1 2027.", "confidence": 65, "category": "research", "geography": "Global", "resolve_date": "2027-03-31", "tags": [ "MDMA", "blinding", "meta-analysis", "methodology" ], "status": "pending", "priority": "medium", "plain_title": "Study published: MDMA blinding doesn't work in most trials", "plain_what": "Scientists will publish a formal research review in a major journal (impact factor above 5 \u2014 meaning it's in the top tier of prestigious publications) that examines all the MDMA-assisted therapy trials and measures exactly how badly the blinding failed. Blinding failure means patients could tell whether they got real MDMA or placebo, which inflates how good the drug looks. This study will quantify the problem across multiple trials and show it's systematic, not a one-off mistake." }, { "date": "2026-05-25", "title": "A major investigative piece exposing financial conflicts of interest between named Republican political figures and venture-backed psychedelic companies will be published by a top-10 U.S. outlet before September 2026.", "confidence": 62, "category": "culture", "geography": "USA", "resolve_date": "2026-09-01", "tags": [ "politics", "Republican", "psychedelics", "venture capital", "investigative" ], "status": "pending", "priority": "medium", "plain_title": "Major news outlet exposes Republican ties to psychedelic companies", "plain_what": "A top-tier US news outlet \u2014 think New York Times, Washington Post, Wall Street Journal, or The Atlantic \u2014 will publish an investigative piece about named Republican politicians or operatives who have financial stakes in psychedelic startups. The piece will document conflicts of interest: these politicians push psychedelic policy or funding while their allies or allies' companies stand to profit. This matters because it exposes how money shapes drug policy and could derail the Republican push to legalize psychedelics." } ]